[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 194037
1. Tokunaga K: Metal Dependence of Signal Transmission through MolecularQuantum-Dot Cellular Automata (QCA): A Theoretical Studyon Fe, Ru, and Os Mixed-Valence Complexes. Materials (Basel); 2010 Aug 06;3(8):4277-4290

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dynamic behavior of signal transmission through metal complexes [L5M-BL-ML5]5+ (M=Fe, Ru, Os, BL=pyrazine (py), 4,4'-bipyridine (bpy), L=NH3), which are simplified models of the molecular quantum-dot cellular automata (molecular QCA), is discussed from the viewpoint of one-electron theory, density functional theory.
  • Among all complexes, Fe complex with bpy BL shows the best result.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ultramicroscopy. 2003 Oct-Nov;97(1-4):55-63 [12801657.001]
  • [Cites] Phys Chem Chem Phys. 2009 Mar 14;11(10):1474-83 [19240923.001]
  • [Cites] Science. 1999 Apr 9;284(5412):289-91 [10195887.001]
  • [Cites] Angew Chem Int Ed Engl. 2003 Mar 3;42(9):1002-5 [12616549.001]
  • [Cites] J Am Chem Soc. 2003 Jan 29;125(4):1056-63 [12537505.001]
  • [Cites] Inorg Chem. 2006 Aug 7;45(16):6378-86 [16878949.001]
  • [Cites] J Phys Chem B. 2006 Nov 2;110(43):21846-9 [17064149.001]
  • [Cites] J Am Chem Soc. 2005 Dec 21;127(50):17819-31 [16351113.001]
  • [Cites] J Am Chem Soc. 2005 Nov 2;127(43):15218-27 [16248664.001]
  • [Cites] J Am Chem Soc. 2003 Dec 10;125(49):15250-9 [14653760.001]
  • [Cites] J Am Chem Soc. 2003 Jun 25;125(25):7522-3 [12812485.001]
  • [Cites] J Am Chem Soc. 2002 Aug 7;124(31):9042-3 [12148995.001]
  • (PMID = 28883329.001).
  • [ISSN] 1996-1944
  • [Journal-full-title] Materials (Basel, Switzerland)
  • [ISO-abbreviation] Materials (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; Creutz-Taube complexes / Fe / Os / QCA / Ru / automaton / density functional theory / mixed-valence complexes / quantum dot / quantum dynamics
  •  go-up   go-down


2. Andarwulan N, Batari R, Sandrasari DA, Bolling B, Wijaya H: Flavonoid content and antioxidant activity of vegetables from Indonesia. Food Chem; 2010 Aug 15;121(4):1231-1235
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ) Bl. (2.27), and <i>Etlingera elatior</i> (Jack) R.M.Sm (1.18).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fitoterapia. 2005 Mar;76(2):194-203 [15752630.001]
  • [Cites] J Agric Food Chem. 2003 Feb 26;51(5):1474-9 [12590501.001]
  • [Cites] Arch Intern Med. 1999 Oct 11;159(18):2170-4 [10527294.001]
  • [Cites] Int J Cancer. 2008 Aug 1;123(3):664-71 [18491403.001]
  • [Cites] Arch Intern Med. 1996 Mar 25;156(6):637-42 [8629875.001]
  • [Cites] J Agric Food Chem. 2001 Jun;49(6):3106-12 [11410016.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2225-32 [17471564.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 15;827(1):127-38 [16087413.001]
  • [Cites] J Nutr Sci Vitaminol (Tokyo). 2007 Jun;53(3):267-76 [17874833.001]
  • [Cites] Phytochemistry. 2003 Jul;63(5):555-67 [12809716.001]
  • [Cites] Plant Foods Hum Nutr. 2009 Mar;64(1):39-45 [18985454.001]
  • (PMID = 28814820.001).
  • [ISSN] 0308-8146
  • [Journal-full-title] Food chemistry
  • [ISO-abbreviation] Food Chem
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / K12 GM074869
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Antioxidant / Cosmos caudatus H.B.K / Flavonoid / Phenolic / Pluchea indica Less / Vegetables
  •  go-up   go-down


3. Coyaud E, Struski S, Prade N, Familiades J, Eichner R, Quelen C, Bousquet M, Mugneret F, Talmant P, Pages MP, Lefebvre C, Penther D, Lippert E, Nadal N, Taviaux S, Poppe B, Luquet I, Baranger L, Eclache V, Radford I, Barin C, Mozziconacci MJ, Lafage-Pochitaloff M, Antoine-Poirel H, Charrin C, Perot C, Terre C, Brousset P, Dastugue N, Broccardo C: Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood; 2010 Apr 15;115(15):3089-97
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study.
  • PAX5 is the main target of somatic mutations in acute B lymphoblastic leukemia (B-ALL).
  • Furthermore, malignant cells carrying PAX5 fusion genes displayed a simple karyotype.
  • Our data shed more light on the high variability of PAX5 alterations in B-ALL.
  • Therefore, it is probable that gene fusions occur early, whereas deletions should be regarded as a late/secondary event.
  • [MeSH-major] B-Cell-Specific Activator Protein / genetics. Cytogenetic Analysis. Mutation / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20160164.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Oncogene Proteins, Fusion; 0 / PAX5 protein, human
  •  go-up   go-down


Advertisement
4. Lovisa F, Mussolin L, Corral L, Pillon M, Cazzaniga G, Biondi A, Rosolen A: IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis. Lab Invest; 2009 Oct;89(10):1182-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGH and IGK gene rearrangements as PCR targets for pediatric Burkitt's lymphoma and mature B-ALL MRD analysis.
  • We recently reported that minimal residual disease (MRD) and minimal disseminated disease (MDD), assessed by long-distance PCR (LD-PCR) for t(8;14), are negative prognostic factors in mature B-cell acute lymphoblastic leukemia (B-ALL) and in Burkitt's lymphoma (BL).
  • Overall, 36 B-ALL and 19 BL cases were analyzed.
  • Multiple PCR reactions were performed for each sample to identify heavy and kappa light-chain rearrangements.
  • A total of 97 RQ-PCR targets (62 for B-ALL, 35 for BL) were analyzed for sensitivity.
  • In 87% of patients (84% of B-ALLs, 95% of BLs) at least one sensitive target was available.
  • All PCR targets identified at diagnosis were preserved at relapse.
  • Our results suggest that MDD and MRD can be successfully studied using a single sensitive Ig target in the great majority of B-ALL and BL cases.
  • [MeSH-major] Burkitt Lymphoma / genetics. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, B-Lymphocyte, Light Chain. Immunoglobulin Heavy Chains / genetics. Immunoglobulin kappa-Chains / genetics. Leukemia, B-Cell / genetics

  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19668242.001).
  • [ISSN] 1530-0307
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


5. Trépo C, Zoulim F: [Treatment of hepatitis B: new perspectives]. Gastroenterol Clin Biol; 2009 Aug-Sep;33(8-9):811-7
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Traitement de l'hépatite B: progrès attendus.
  • Despite the development of new anitiviral agents, the treatment of chronic hepatitis B remains a major clinical challenge.
  • The development of true combination therapy is highly desirable to fulfil the objective of long-term viral suppression, clearance of viral cccDNA and infected cells and ultimately cure of the disease.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19560888.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antiviral Agents
  •  go-up   go-down


6. Koren-Michowitz M, Rahimi-Levene N, Volcheck Y, Hardan I, Kornberg A: Rituximab monotherapy as interim therapy in precursor B-ALL adults during periods of hepatic toxicity: report of two cases. Am J Hematol; 2006 Dec;81(12):979-80
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both patients were able to continue further chemotherapy, underwent an Allo BMT and are now 10-12 months after diagnosis in a continuous CR.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Agents / administration & dosage. Bone Marrow Transplantation. Burkitt Lymphoma / therapy

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019690.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


7. Asselah T, Lada O, Boyer N, Martinot M, Marcellin P: [Treatment of chronic hepatitis B]. Gastroenterol Clin Biol; 2008 Aug-Sep;32(8-9):749-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Traitement de l'hépatite chronique B.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18775613.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antiviral Agents; 9008-11-1 / Interferons
  • [Number-of-references] 130
  •  go-up   go-down


8. Cobaleda C, Sánchez-García I: B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin. Bioessays; 2009 Jun;31(6):600-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin.
  • B-cell acute lymphoblastic leukaemia (B-ALL) is a clonal malignant disease originated in a single cell and characterized by the accumulation of blast cells that are phenotypically reminiscent of normal stages of B-cell differentiation.
  • B-ALL origin has been a subject of continuing discussion, given the fact that human disease is diagnosed at late stages and cannot be monitored during its natural evolution from its cell of origin, although most B-ALLs probably start off with chromosomal changes in haematopoietic stem cells.
  • However, the cells responsible for maintaining the disease appear to differ between the different types of B-ALLs and this remains an intriguing and exciting topic of research, since these cells have been posited to be responsible for resistance to conventional therapies, recurrence and dissemination.
  • The results from these different reconstitution experiments and their interpretations are compared in this review in the context of normal B-cell developmental plasticity.
  • [MeSH-major] B-Lymphocytes / physiology. Leukemia, B-Cell / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Animals. Biomarkers, Tumor / metabolism. Cell Differentiation / physiology. Humans. Neoplastic Stem Cells / cytology. Neoplastic Stem Cells / physiology. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19444834.001).
  • [ISSN] 1521-1878
  • [Journal-full-title] BioEssays : news and reviews in molecular, cellular and developmental biology
  • [ISO-abbreviation] Bioessays
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 63
  •  go-up   go-down


9. Li S: Src kinases as targets for B cell acute lymphoblastic leukaemia therapy. Expert Opin Ther Targets; 2005 Apr;9(2):329-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Src kinases as targets for B cell acute lymphoblastic leukaemia therapy.
  • The participation of Src kinases in the induction of BCR-ABL-induced B cell acute lymphoblastic leukaemia (B-ALL), but not chronic myeloid leukaemia (CML), demonstrates cell type-specific signalling in Philadelphia chromosome-positive (Ph+) leukaemias.
  • Leukaemic stem cells may exist in Ph+ B-ALL, and eradication of this group of cells would provide a curative method for this disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / enzymology. Drug Delivery Systems / methods. Protein Kinase Inhibitors / therapeutic use. src-Family Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15934919.001).
  • [ISSN] 1744-7631
  • [Journal-full-title] Expert opinion on therapeutic targets
  • [ISO-abbreviation] Expert Opin. Ther. Targets
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; EC 2.7.10.2 / src-Family Kinases
  • [Number-of-references] 114
  •  go-up   go-down


10. Nygren MK, Døsen G, Hystad ME, Stubberud H, Funderud S, Rian E: Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines. Br J Haematol; 2007 Feb;136(3):400-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wnt3A activates canonical Wnt signalling in acute lymphoblastic leukaemia (ALL) cells and inhibits the proliferation of B-ALL cell lines.
  • Acute lymphoblastic leukaemia (ALL) is the most common malignancy in children.
  • This study found that Wnt3A induced beta-catenin accumulation in both primary B-ALL cells and B-ALL leukaemia cell lines.
  • Further, Wnt3A was shown to induce nuclear translocation of beta-catenin and TCF/Lef-1 dependent transcriptions in the B-ALL cell line Nalm-6.
  • Functional analyses showed that Wnt3A inhibited the proliferation of several, but not all, B-ALL cell lines studied.
  • [MeSH-major] Burkitt Lymphoma / metabolism. Signal Transduction / physiology. Wnt Proteins / pharmacology
  • [MeSH-minor] Blotting, Western / methods. Cell Line, Tumor. Cell Proliferation. Gene Expression Profiling. Humans. Microscopy, Confocal. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins / genetics. Proto-Oncogene Proteins / metabolism. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Statistics, Nonparametric. Transcription Factors / genetics. Transcription Factors / metabolism. Tumor Cells, Cultured. Wnt3 Protein. Wnt3A Protein. beta Catenin / genetics. beta Catenin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156404.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / WNT3A protein, human; 0 / WNT5A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / beta Catenin
  •  go-up   go-down


11. Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, D'Amico G: Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol; 2006 Sep;34(9):1219-29
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Cytokine-induced killer (CIK) cells are ex vivo expanded cells enriched in CD3(+)CD56(+) natural killer T (NKT) cells with major histocompatibility-unrestricted cytotoxicity against several tumoral targets, except B-lineage acute lymphoblastic leukemia (B-ALL).
  • MATERIAL AND METHODS: CIK cells were expanded ex vivo for 21 days and analyzed for expression of adhesion molecules and chemokine receptors regulating adhesion and homing toward leukemia-infiltrated tissues.
  • CIK cells were then transduced with the anti-CD19-zeta-internal ribosomal entry site-green fluorescent protein retroviral vector and characterized for their cytotoxicity against B-ALL cells in a (51)Cr-release assay and for their trafficking properties, including chemotactic activity, adhesion and transendothelial migration, and metalloproteases-dependent invasion of Matrigel.
  • CONCLUSION: The potential capacity to localize into leukemia-infiltrated tissues of anti-CD19 chimeric receptor-redirected CIK cells, together with their ability to efficiently kill B-ALL cells, suggests that modified-CIK cells represent a valuable tool for leukemia immunotherapy.
  • [MeSH-major] Antigens, CD19 / immunology. Burkitt Lymphoma / immunology. Cell Movement / immunology. Cytotoxicity, Immunologic. Killer Cells, Lymphokine-Activated / immunology. Recombinant Fusion Proteins / immunology. T-Lymphocytes / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16939815.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD19; 0 / Receptors, Chemokine; 0 / Recombinant Fusion Proteins
  •  go-up   go-down


12. Morović M: [Treatment of chronic hepatitis B]. Acta Med Croatica; 2005;59(5):429-32
Hazardous Substances Data Bank. LAMIVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Antiviral Agents / therapeutic use. Humans. Interferon Type I / therapeutic use. Lamivudine / therapeutic use. Recombinant Proteins

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381239.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon Type I; 0 / Recombinant Proteins; 2T8Q726O95 / Lamivudine
  •  go-up   go-down


13. Morović M, Troselj-Vukić B, Klarin I, Hrstić I, Ostojić R: [Chronic hepatitis B therapy]. Acta Med Croatica; 2009 Dec;63(5):391-5
Genetic Alliance. consumer health - Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chronic hepatitis B therapy].
  • [Transliterated title] Terapija kronicnog hepatitisa B.
  • Chronic hepatitis B is associated with the development of cirrhosis in more than one third of patients and in a large proportion of patients with hepatocellular carcinoma.
  • Current standard treatment includes pegylated interferon alfa-2a and five oral nucleoside/nucleotide analogues: entecavir, tenofovir, adefovir, telbivudine and lamivudine (listed according to antiviral efficacy).
  • The advantage of interferon treatment is the possibility of long-term remission in one third of carefully selected HbeAg+ patients without development of resistance.
  • However, interferon treatment is not efficient in the majority of patients.
  • The advantage of treatment with nucleoside and nucleotide analogues is the possibility to suppress HBV DNA to undetectable levels in 70%-90% of patients.
  • However, analogue treatment is a long-term treatment (possibly life-long) and is associated with the development of resistance.
  • [MeSH-major] Hepatitis B, Chronic / drug therapy
  • [MeSH-minor] Antiviral Agents / therapeutic use. Humans. Interferon-alpha / therapeutic use. Polyethylene Glycols / therapeutic use. Recombinant Proteins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198897.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


14. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel.
  • : e17575 Background: We (MC) previously established a definition of laboratory (LTLS) and clinical TLS (CTLS) and associated grading system (Cairo et al, BJH. 2004).
  • It still remains to be determined which patients at risk of developing TLS should receive R versus A as initial TLS prophylaxis.
  • METHODS: We convened an international panel (N = 17) of experts in pediatric and adult hematological malignancies and solid tumors (ST) to develop a medical decision tree for the P and T of TLS based on the risk classification (low, medium, high) and management recommendations of Coiffier et al (J Clin Oncol.
  • 2008) Results: Patients without evidence of LTLS were assigned to either low-risk disease (LRD), medium-risk (MRD), or high-risk (HRD).
  • Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement.
  • HRD was assigned to patients with either B-ALL, ALL/AML ≥100K/mm<sup>3</sup>, BL/LL stage III/IV, and/or high LDH, DLBCL/PTCL/MCL/ATL with bulky and elevated LDH and patients with MRD with renal impairment/involvement.
  • MRD consisted of ALL ≤100K/mm<sup>3</sup>, AML 25-100K/mm<sup>3</sup>, BL/LL stage I/II and low LDH, childhood ALCL, DLBCL/PTCL/MCL/ATL non-bulky but elevated LDH, CLL treated with targeted therapy, and LRD with renal impairment/involvement.
  • LRD consisted of ST (except bulky sensitive to cytotoxic therapy [MRD]), CML, MM, HL, other NHL and AML <25K/mm<sup>3</sup>.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to gather data on the epidemiology of AIDS-defining (AD) and non-AIDS-defining (NAD) malignancies in HIV-positive patients (pts) in Germany in the past decade.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • 253 (45.8%) were AD as follows: 132 Kaposi Sarcomas, 109 aggressive B-cell lymphomas, 12 invasive cervix carcinomas.
  • The B-cell lymphomas further included 28 Burkitt's lymphomas, 30 DLBCL, 9 Castleman diseases, 8 primary cerebral lymphomas.
  • Among the 299 cases (54.2%) of NAD malignomas were 213 solid tumors including 71 anal carcinomas (= 33.5% of all NAD malignancies) and 85 hemoblastoses including 29 Hodgkin lymphomas (= 9.6% of all NAD malignancies).
  • Interestingly, only 1 of 8 primary cerebral lymphomas has been reported after 2001.
  • The number of pts with Hodgkin's lymphoma has increased constantly from 2000 to 2007.
  • Anal carcinomas and Hodgkin's lymphomas in particular were markedly more prevalent in our HIV-positive cohort compared to published reports of the general population.
  • The incidence of primary cerebral lymphomas seems to decrease, whereas the incidence of Hodgkin's lymphoma is increasing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Tsujimura H, Mimura N, Ise M, Sakai C, Shimada H, Nagata M, Kumagai K: Incidence of therapy-related leukemia following chemoradiotherapy for esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15663

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of therapy-related leukemia following chemoradiotherapy for esophageal cancer.
  • : e15663 Background: The combination of chemotherapy and concurrent radiotherapy (CRT) has recognized as a curative alternative for several stage of esophageal cancer.
  • METHODS: From July 2000 to March 2008, 348 patients with esophageal squamous cell carcinoma underwent CRT.
  • RESULTS: Four patients, who achieved CR after CRT, developed leukemia.
  • Case1, 60-yo-male, developed overt acute myeloid leukemia (AML) from myelodysplastic syndrome 48 months after CRT.
  • Case3, 72-yo-male, developed Burkitt leukemia with t(8;14)(q24;q32) 19 months after CRT.
  • Case4, 65-yo-male, developed myeloid crisis of chronic myelogenous leukemia with complicated abnormalities including t(9;22)(q34;q11) 48 months after CRT.
  • Case 1 and 3 had localized disease and received single course of neoadjuvant CRT.
  • Case 2 and 4 had advance disease and received 2 courses of CRT.
  • All patients eventually died of leukemia.
  • To this end, atypical cytogenetic abnormalities seen in the present cases give a new insight into the biology of therapy-related leukemia.
  • Notably, this is the first report presenting the incidence of secondary leukemia by nedaplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962759.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Mir AR Jr, Sazawal Sazawal S, Saxena A, Saxena R: High-sensitivity detection of M351T, F317L, and F311C BCR-ABL kinase domain mutation in chronic myeloid leukemia patients treated with novel tyrosine kinase inhibitors (TKIs) imatinib and dasatinib. J Clin Oncol; 2009 May 20;27(15_suppl):7061

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-sensitivity detection of M351T, F317L, and F311C BCR-ABL kinase domain mutation in chronic myeloid leukemia patients treated with novel tyrosine kinase inhibitors (TKIs) imatinib and dasatinib.
  • Group A All 100 CML patients were treated with imatinib at conventional dose of 400 mg/day and were screened for M351T mutation after three years of imatinib initiation. (40%) 40/100 were positive for M351T mutation consequently 20/40 were treated with high dose imatinib at 600 to 800 or 1,000 mg/day.
  • 2/5 died, three progressed to advanced disease.
  • After 10 months, 4/10 developed a more fatal mutation in 315 and consequently 2/4 died and one progressed to advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Adamia S, Avet-Loiseau H, Amin SB, Moreau P, Minvielle SS, Treon S, Li C, Anderson KC, Munshi N: Clinical and biological significance of microRNA profiling in patients with myeloma. J Clin Oncol; 2009 May 20;27(15_suppl):8539

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and biological significance of microRNA profiling in patients with myeloma.
  • : 8539 MicroRNA, a small endogenous RNA regulating specific expressed gene function has been implicated in normal biological processes as well as in malignant transformation.
  • Here we have investigated the role of microRNAs in multiple myeloma (MM) biology, and their influence on prognosis and clinical outcome.
  • We evaluated profiles of 384 microRNAs in CD138+ MM cells from 79 patients with MM, 11 cell lines and 9 healthy donors using qRT-PCR based microRNA array.
  • Group A clustered with MM cell lines, indicating more aggressive course of disease.
  • The unsupervised clustering of all MM samples showed consistent change in miR-146b, -140, -145, -125a, -151, -223, -155, let-7f, indicative of a role of these microRNA in myelomagenesis; while supervised analysis of samples within groups A and B identified modulated expression of different sets of miRNAs.
  • We further analyzed the effect of microRNA on clinical outcome.
  • Functional analysis by modulating miRNAs 585, 155 and let-7f showed change in levels of predicted genes with consequent biological effect on growth and apoptosis in MM cell line.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960934.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Dasoula A, Hatzimichael E, Dranitsaris G, Benetatos L, Syed N, Vassou A, Stebbing J, Crook T, Bourantas K: Snk/Plk2 CpG methylation in patients with multiple myeloma. J Clin Oncol; 2009 May 20;27(15_suppl):e19532

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e19532 Background: We previously showed that polo like kinase 2 (Snk/Plk2) is subject to methylation-dependent transcriptional silencing in a very high frequency in Burkitt lymphomas.
  • METHODS: Bone marrow samples from individuals with MM were obtained at diagnosis and in 5 cases at disease progression as well.
  • Logistic regression analyses were used to measure the association between gene methylation and the development of advanced disease (DS≥II), extramedullary disease, bone disease, anemia (Hb 10 mg/dl), serum albumin and beta 2 microglobulin levels.
  • There was no association between the methylation status of the gene and relevant clinical parameters.
  • Further evaluation in a larger sample of patients is needed in order to better define the prognostic and clinical value if any of Snk/Plk2 methylation in MM.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961026.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Qu P, Haessler J, Barlogie B, Shaughnessy J: Bone marrow microenvironment (ME) associated genes identified prior to all altered 48 hours after bortexomib test-dose application and prognosis of multiple myeloma (MM) treated with total therapy 3 (TT3). J Clin Oncol; 2009 May 20;27(15_suppl):8520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Bone marrow biopsies were obtained at baseline (BL) prior to and 48hr after BOR (PB) in 70 of 303 patients receiving TT3a (training set) and in 45 of 177 patients enrolled in TT3b (test set).
  • Among 608 ME genes distinguishing BL and PB training samples, 58 were identified as being significantly linked to short event-free survival (EFS).
  • Additionally, 20 ME genes were selected whose BL expression predicted OS, arriving at a BL score (BL-ME-S).
  • The BL-ME-S distinguished OS and EFS in the training set of 70 patients, with 3-yr OS and EFS estimates of 92% and 91% among the 50 patients with low and 54% and 45% in the 20 patients with high BL-ME-S (both P<0.0001).
  • These data were validated in 113 patients with only BL-ME data: 3-yr OS and EFS were 90% and 85% among the 89 patients with low as opposed to 70% and 55% among the 14 patients with high BL-ME-S (p=0.001, p=0.002).
  • TT3 survival was independently significantly affected by PB-ME-S (OS: HR=12.74, p=0.002; EFS: HR=14.32, p<0.001) and BL-ME-S (EFS: HR=3.10, p=0.045), whereas the univariately significant role of BL-PC-S for both endpoints could not be confirmed on multivariate analysis.
  • Key genes shared by both PB-ME-S and BL-ME-S models are involved in endothelial and mesenchymal stem-cell signaling, the details of which will be reported at the meeting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960896.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Bower M, Syed N, Papoudou-Bai A, Stebbing J, Naresh K, Hatzimichael E, Powles S, Crook T: Methylation reversal in high-grade B lymphoma cell lines and novel epigenetic changes conserved between immunocompetent and HIV-positive hosts. J Clin Oncol; 2009 May 20;27(15_suppl):8585

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation reversal in high-grade B lymphoma cell lines and novel epigenetic changes conserved between immunocompetent and HIV-positive hosts.
  • : 8585 Background: Methylation-dependent transcriptional silencing is an important mechanism of tumour suppressor gene inactivation in neoplasia, including lymphoma.
  • METHODS: Pharmacological "unmasking" of transcriptionally silenced genes in B lymphoma cell lines was achieved using 5' deazacytidine ± Trichostatin A and subsequent analysis of mRNA levels on micro-array.
  • Candidate genes thus identified, were further analysed by qPCR, methylation-specific PCR (MSP) and bisulphite sequencing in B lymphoma cell lines and by MSP in clinical samples from sporadic (immunocompetent) (18 cases) and HIV-infected patients (14 cases).
  • Samples in both patient groups were diffuse large B cell lymphoma (DLBCL) and Burkitt's lymphoma (BL).
  • Additionally, we analysed 8 cases of marginal zone lymphoma (MZL) from the immunocompetent group.
  • RESULTS: We report the identification of 13 novel genes, not previously described in the literature, which are subject to methylation-dependent transcriptional silencing in high-grade lymphoma and whose expression can be reactivated by demethylating agents.
  • The frequency of methylation in individual genes varied from approximately 10% to 75% in specific lymphoma subtypes, but was in general similar in high grade lymphomas in immunocompetent and HIV-infected hosts.
  • CONCLUSIONS: Using pharmacological reversal of methylation, we have identified a number of genes, not previously implicated in human neoplasia, which are subject to transcriptional silencing in high-grade B lymphomas.
  • Detection of methylated DNA of one or more of these genes may have utility as biomarkers of clinical outcome in each patient group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Parker S, Berman D, Bennett KL, Alaparthy S, Tsuchihashi Z, Chasalow SD, Zhan P: Increased humoral and cellular immunity in patients (pts) with advanced melanoma treated with ipilimumab. J Clin Oncol; 2009 May 20;27(15_suppl):3031

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3031 Background: Ipilimumab is an anti-CTLA-4 monoclonal antibody (Ab) that overcomes T-cell suppression.
  • Humoral response to 5 tumor antigens (Ag) and a control Ag (DHFR) were examined at baseline (BL) and at Wks 4, 8-9, and 12.
  • Peripheral T-cell populations were evaluated through flow cytometry at BL, Wk 4, and Wk 12.
  • Increases from BL in humoral responses to pneumococcal (40-50/78 pts, depending on Ab) and tetanus (58/78 pts) vaccines were noted, even in pts who did not receive on-study pneumococcal (4-9 pts) or tetanus (7 pts) vaccines.
  • Maximum increase from BL of ≥ 5-fold titer (clinically meaningful threshold) in humoral response to tumor Ag MELANA (23.2% of pts), SSX2 (20.3%), NYES01 (18.8%), MAGEA4 (10.1%), and P53 (4.3%) (DHFR, 4.3%) was noted without tumor vaccines.
  • Tumor Ag response was not associated with clinical activity (complete or partial response, or stable disease ≥ 24 wks).
  • Significant increases from BL in percents of HLA-DR+ CD4+ (p = 9.3x10<sup>-7</sup>), HLA-DR+ CD8+ (p = 0.018), and ICOS+ CD4+ (p = 0.0027) effector T cells were noted.
  • Change in tumor Ag response was not associated with clinical activity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962083.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Horak CE, Lee FY, Xu L, Galbraith S, Baselga J: High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: A retrospective analysis. J Clin Oncol; 2009 May 20;27(15_suppl):3587

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anti-microtubule agent ixabepilone (Ixa) demonstrates efficacy in βIII over-expressing tumor models resistant to taxanes and has clinical activity in patients with TN BC.
  • Using intrinsic gene clustering, BC tumors from the Ixa neoadjuvant study CA163-080 (080) and the International Genome Consortium (IGC) were defined as basal-like (BL), luminal-like, Her2-overexpressing (Her2+) or normal-like subtypes.
  • Clinical responses for 080 patients were compared to βIII expression levels.
  • RESULTS: For both cohorts, mean expression of TUBB3 was higher in BL and Her2+ tumors (one-way ANOVA and Tukey's HSD test; both p < 0.001).
  • In 080 and IGC cohorts, high expressors represent >50% of patients in BL and Her2+ subtypes and ∼20% of other BC subtypes.
  • CONCLUSIONS: BC patients with TN, BL and Her2+ tumors have higher βIII expression.
  • These data suggest high βIII in BL and TN BC may contribute to the aggressiveness of these subtypes and predict for Ixa clinical response.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961747.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Bechstein WO, Lang H, Köhne C, Parisi F, Raab HR, Frilling A, Konopke R, Weitz J, Stroszczynski C, Folprecht G: Resectability and agreement between surgeons: Review of CT and MR scan of the CELIM study: (Multicenter randomized trial of cetuximab/FOLFOX versus cetuximab/FOLFIRI in unresectable liver metastases. J Clin Oncol; 2009 May 20;27(15_suppl):4091

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: During two workshops, CT- or MRI scans at baseline (BL) and after 4 months treatment (follow-up, F-U) of CELIM-patients (pts) were presented to surgeons (surg.) who were blinded to each other, the time of investigation (BL or F-U) and clinical data.
  • (1) resection, (2) exploration, (3) borderline resectable (prior chemotherapy preferred) or (4) non-resectable If scans were allocated to category (3) or (4), the reason (technical or poor prognosis) was stated.
  • Inter-observer variability was evaluated by a reduced model, too: operation (1+2), borderline, primary chemo therapy preferred (3) and non-resectable, chemotherapy (4).
  • Both, BL and F-U scans, were available for 75 pts (68% of study pts).
  • During the review, 24 pts changed from 'non-resectable' at BL to 'resectable' at F-U, 5 pts from 'resectable' to 'non-resectable', 29 pts remained 'non-resectable', and 17 pts 'resectable' (19 pts more resectable at F-U; chi-square: p=.021).
  • R0 resection was actually performed in 16/29 pts classified as 'resectable' (55%) and 13/54 pts not classified as 'resectable' (24%) according to presented BL- images.
  • Regarding the clinical approach, different surgeons had a high degree of agreement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961671.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM: Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).
  • Twenty-one pts had pre-B ALL, 5 pts pre-T/T ALL, 1 pt mature B ALL, and 3 pts biphenotypic acute leukemias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Crowley J, Bolejack V, Robert K, Anderson K, Barlogie B: Prognostic factor analyses of myeloma (MM) survival outcomes on intergroup trial S9321 (int 0141): Examining whether different variables govern different time segments of survival. J Clin Oncol; 2009 May 20;27(15_suppl):8599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We therefore examined, in S9321, PF that were associated with overall survival (OS) from baseline (BL) and from 3 subsequent landmarks 3, 5, and 7 years later (LM3, LM5, LM7).
  • The BL model identified age (>60yr), hemoglobin (<10g/gL), platelet count (<130,000/uL), albumin (<3.5g/dL), B2M (>3.5g/dL), calcium (>10mg/dL), creatinine (>2mg/dL), LDH (>190U/L), performance status (PS, >1), IL-6 level (>140mg/L) and plasma cell labeling index (PCLI, >1%) as being univariately associated with short OS, while age (p=0.002), platelet count (p=0.04), calcium (p<0.001), B2M (p=0.002), LDH (p=0.010) and PCLI (p<0.001) retained significance in multivariate analysis.
  • While associated univariately with OS from BL, CRP, platelet count, hemoglobin, albumin, calcium, creatinine, LDH, IL6 and PS all failed to affect OS from later LM times.
  • CONCLUSIONS: Whereas the initial 3 years of OS are governed by a combination of features related to disease aggressiveness (LDH, calcium, albumin, CRP), tumor burden (hemoglobin, platelet count) and host tolerance (PS, creatinine), B2M and PCLI as reflectors of tumor burden and proliferation have sustained long-term OS implications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962307.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Nair B, Shaughnessy J, Alsayed Y, Haessler J, van Rhee F, Hollmig K, Pineda-Roman M, Crowley J, Barlogie B: Gene expression profiling (GEP)-defined risk and molecular subgroups assessed at baseline and at relapse: Collective impact on post-relapse survival of multiple myeloma (MM) treated with total therapies 2 and 3. J Clin Oncol; 2009 May 20;27(15_suppl):8589

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we examine, among patients with available GEP data at baseline (BL) and relapse (REL), the contributions of both observations on post-relapse survival (PRS).
  • METHODS: Paired REL-BL GEP data were available in 77 patients, while information on metaphase cytogenetic abnormalities (CA) was obtained in 76 patients at both time-points.
  • RESULTS: PRS was significantly affected by both BL and REL HR status so that, among the 52 patients with LR at BL, HR status at REL conferred significantly poorer outcome compared to those with LR at REL (p=0.0005) with 30-mo estimates of 71% v 13%; likewise, among the 25 patients with HR at baseline, HR present also at relapse further diminished PRS (p=0.09) with 30-mo estimates in both settings of less than 20%.
  • Similar considerations for CA status revealed, among the 29 patients without CA at BL, marked attrition of PRS with CA v no CA at REL with 30-mo estimates of 29% v 81% (p=0.04); for the 47 patients with CA at BL, CA also at REL further diminished the poor PRS from 46% to 22% (p=0.06).
  • When all standard BL and REL prognostic factors were examined in a multivariate model, GEP-derived HR contributed to poor PRS both when present at BL (HR=2.79, p=0.005) and at REL (HR=2.77, p=0.002), in addition to CA at BL (HR=2.44, p=0.018).
  • CONCLUSIONS: In estimating PRS in TT protocols, genetic characteristics at BL (HR, CA) have enduring adverse consequences aggravated further by HR status at REL.
  • Therefore, in HR/CA BL settings, aiming at REL prevention appears as the best overall treatment strategy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962296.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Weyl Ben Arush M Sr, Hersalis Eldar A, Abrahami G, Attias D, Ben Barak A, Dvir R, Gabriel H, Kapelushnik J, Kaplinsky H, Vilk-Revel S: Burkitt lymphoma in children: The Israel Society of Pediatric Hematology Oncology retrospective study. J Clin Oncol; 2009 May 20;27(15_suppl):10051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma in children: The Israel Society of Pediatric Hematology Oncology retrospective study.
  • : 10051 Background: From 2000 to 2005, the Israel Society of Pediatric Hematology Oncology studied the results of the FAB-LMB 96 protocol in children with B cell lymphoma.
  • Fifty patients (57%) were classified as burkitt lymphoma, 5 (5.7%) as burkitt-like lymphoma, 22 (25%) as diffuse large B cell (DLBC), 9 (10.2%) as burkitt leukemia.
  • Initial disease sites included the abdomen in 43%, head and neck in 45%, mediastinum in 7%.
  • In group A: there were neither events nor deaths in this group, 6 patients relapsed in group B, among them 4 patients had died, tumor lysis syndrome in 3 patients, death of toxicity in 1 patient.
  • OS according to primary site: bone and ovary (100%), head and neck (95%), abdomen (92%) and mediastinum (50%) (p = 0.003).
  • All of the mediastinal tumors were of DLBC origin, but when comparing the DLBC to other histologies, no significant difference in outcome were found.(DLBC: 81.8%, other B line: 90.9%).
  • CONCLUSIONS: In nonresected mature B cell lymphoma of childhood and adolescence with no BM or CNS involvement, a 93% cure rate was achieved.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962447.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Reiter A, Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, Mann G, Schrappe M: Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol; 2009 May 20;27(15_suppl):10000

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin lymphoma (NHL).
  • : 10000 Background: Pediatric mature B-cell NHL differ from aggressive B-NHL of adults in terms of biology and treatment outcome.
  • In contrast to adults, rituximab (Rx) is not established in the treatment of pediatric B-NHL has not be determined yet.
  • Even the activity of Rx in pediatric B-NHL is not determined.
  • We conducted a phase II window study to examine the activity of Rx in newly diagnosed pediatric B-NHL.
  • METHODS: Eligibility: age < 19 y, CD20 + B-NHL, ≥ 1 measurable lesion/s, informed consent.
  • Exclusion: Lansky performance scale 5, pre-treatment, impaired renal-, heart-, liver-function, hepatitis B, pre-existing disease, pregnancy.
  • NTC °3/4 toxicities: general condition 16%, fatigue 13%, anaphylaxis (chill/fever/bronchospasm) 6 (1/2/4)%, infection 3%, S-GOT/GPT 10%, acute tumor lysis (ATL) 7%, capillary leakage (0), toxic death (0).
  • RR by histology: BL/B-ALL 29/68, DLBCL 6/14, juvenile follicular lymphoma 1/2, PMBCL 1/1, B-NHL nfs 0/2.
  • Fifty pts were non-RPs.
  • CONCLUSIONS: Although the RR was lower than requested Rx as single agent is active in pediatric B-NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962545.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Khattab TM, Jastaniah WA, Felimban SK, Elemam N, Abdullah K, Ahmed B: How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia. J Clin Oncol; 2009 May 20;27(15_suppl):10048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia.
  • : 10048 Background: T-cell acute lymphoblastic leukemia (T-ALL) is representing 10-15% of pediatric ALL.
  • OBJECTIVES: We reviewed all patients diagnosed with T-ALL to assess risk classification according to NCI criteria, type of therapy received, overall survival and causes of mortality.
  • METHODS: Retrospective review of all patients files diagnosed with T-ALL from 1989 until now with data collection including; sex, age, white cell count (WBCs), CNS disease, type of protocol used, length of survival, overall survival, cause of death (toxic, disease).
  • Median WBCs 50,000/Cmm (range: 1.500-619,000/Cmm) and positive CNS at diagnosis 10/52 (20%).
  • Overall survival 27/52 (52%) and 25 pts. died (48%); 15 secondary to disease recurrence (9 on UKALL, 4 BFM, 2 CCG 1961); 4 during induction, 1 fulminant hepatic failure, 1 tumor lysis syndrome, and 4 due to toxicities (mucormycosis, staphylococcal toxic shock syndrome, CMV pneumonia, pseudomonas sepsis).
  • Mean length of survivors 4 year (range 4-140 month) and mean length for non-survivors 1 year (range 0.1-40 months).
  • Further risk and response stratification in addition to intensification of therapy for T-cell ALL in our center may prove to be beneficial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Heymach J, Jonasch E, Wang X, Du DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ: A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol; 2009 May 20;27(15_suppl):5114

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC).
  • Plasma was collected from 69 pts at baseline (BL; SR 34, SR+IFN 35), 59 on day (D) 28, and 57 pts on D56.
  • Osteopontin (OPN), soluble carbonic anhydrase 9 (sCA9), placental growth factor (PlGF), collagen type IV (ColIV) and sVEGFR-2 were measured by ELISA.
  • The primary objective of this analysis was to establish a CAF signature based on a set of individual markers at BL with a significant and differential impact on the association between treatment arm and PFS.
  • RESULTS: Among 52 CAFs available at BL, higher than median EGF concentrations associated with poor outcome independently of treatment arm, whereas low IL-2 had the opposite effect (p = 0.003 for both).
  • Only OPN showed a significant treatment by factor interaction at BL (p < 0.01), suggesting that OPN has a differential effect on PFS in the two arms.
  • A 6-marker CAF signature at BL containing OPN, sCA9, VEGF, sVEGFR-2, ColIV, and TRAIL demonstrated predictive value on PFS.
  • Broad-based screening of circulating CAFs may identify predictive and prognostic biomarkers in the context of clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964391.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Luong NV, Kantarjian HM, Faderl SH, Thomas DA, Vu KD: Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL). J Clin Oncol; 2009 May 20;27(15_suppl):7059

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurence of venothromboembolism (VTE) in patients (pts) with acute lymphocytic leukemia (ALL), Burkitt's leukemia/lymphoma (BL), or lymphoblastic leukemia (LL).
  • Although neoplastic diseases are known risk factors for the development of VTE, little is known about the incidence and predisposing factors of VTE among leukemia patients (pts).
  • METHODS: We performed a retrospective study to determine the incidence and risk factors associated with development of VTE among pts with ALL, BL, LL at M. D.
  • Pts who used oral contraception or hormone replacement therapy (OCP/HRT) were 2 times (95% CI: 1.07-3.92) more likely to develop VTE than non-users.
  • In a multivariate model, significant predictors of VTE were age 40-59 yrs, plt count 50-99 x 10<sup>9</sup>/L, diagnosis of Ph-positive ALL, history of VTE, and OCP/HRT use.
  • In addition to traditional risk factors, disease-specific features may also predispose pts to higher VTE risk.
  • Further studies should be done in other leukemias to establish guidelines in the prevention and management of VTE in pts with leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961450.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Pandit-Taskar N, Comenzo RL, Hassoun H, Hoover E, Borkar S, Reidel E, Cohen A, Surti C, Nimer SD, Landau HJ: FDG PET/CT (FDG PET) in evaluation of response in patients with multiple myeloma (MM) treated with bortezomib, pegylated liposomal doxorubicin, and dexamethasone. J Clin Oncol; 2009 May 20;27(15_suppl):8533

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pts were assessed using serial FDG PET imaging: at baseline (BL), after 3 cycles of BDD and at end of study (EOS).
  • MM disease response was assessed according to the International Myeloma Working Group (IMWG) criteria.
  • RESULTS: Median age of pts enrolled was 59 yrs (range 41-80), 62% male, 38% ISS II, 47% ISS III, and 15% ISS I with soft-tissue disease.
  • The other pts are as follows: 2 had negative FDG PET at BL, 6 were taken off study (5 for toxicity and 1 with CR), 1 FDG PET was unable to be compared due to technical differences and 6 pts have not completed treatment.
  • There was little agreement between MM disease response and FDG PET responses (Kappa statistic, 0.05).
  • One had granulomatous disease rather than MM at biopsy.
  • In 1 pt with progression of disease with a progressive skull-based plasmacytoma, FDG PET was scored as PR by EORTC criteria.
  • CONCLUSIONS: There was poor agreement between FDG PET response and MM disease response by IMWG criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960928.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Cairo MS, Sposto R, Gerrard M, Waxman I, Goldman S, Auperin A, Pinkerton R, Raphael M, McCarthy K, Perkins SL, Patte C: Advanced stage, elevated LDH, primary sites, but not adolescent (A) age (≥ 15 years) as risk factors for disease progression in childhood (C) and adolescent (A) mature B-NHL: Report of the FAB/LMB 96 international trial. J Clin Oncol; 2009 May 20;27(15_suppl):10032

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced stage, elevated LDH, primary sites, but not adolescent (A) age (≥ 15 years) as risk factors for disease progression in childhood (C) and adolescent (A) mature B-NHL: Report of the FAB/LMB 96 international trial.
  • : 10032 Background: We recently reported the results in C & A with low risk (group A), intermediate risk (group B) and high risk (group C) mature B-NHL treated on FAB/LMB 96 (Gerrard et al, Br J Haematol, 2008; Patte et al, Blood, 2007; Cairo et al, Blood, 2007, respectively).
  • Adolescent age (15-21 yrs) has historically been considered to be an independent risk factor for poor outcome in subsets of mature B-NHL (Hochberg/Cairo et al, Br J Haematol, 2008; Burkhardt et al, Br J Haematol 2005; Cairo et al, Br J Haematol, 2003).
  • METHODS: We analyzed the EFS of all pts treated on FAB/LMB 96 and the following risk factors were significant in a univariate and Cox multivariate analysis: age (<15 vs ≥15 yrs), stage I/II vs III/IV, primary sites, LDH <2 vs ≥2 NL and histology (DLBCL vs BL/BLL).
  • CONCLUSIONS: With the use of modern short but intense FAB-LMB 96 therapy, adolescent age is no longer a poor risk factor in children with mature B-NHL.
  • The independent risk factors identified in this study (stage, LDH, primary site) for decreased EFS in C & A mature B-NHL will form the basis of the next risk adapted international pediatric mature B-NHL trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962579.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Vicente A, García-Martínez E, Gonzalez-Billalabeitia E, Zafra M, Castilla-Llorente C, García-García T, Macías J, García-Garre E, Vicente V, Ayala de la Peña F: Prognostic value of decrease on blood lymphocytes in breast cancer patients undergoing primary chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):e11537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e11537 Background: There is evidence about chemotherapy creating a better tumor control by inmune system.
  • Neoadjuvant treatment is an excellent situation to study tumor behaviour.
  • The aim of this study is to determine whether decreases on blood lymphocytes (BL) absolute number have a prognostic significance on women with breast cancer receiving primary chemotherapy (PC).
  • We collected data on BL before the first cycle of PC (basal BL), just before second doxorubicin- cyclophosphamide (AC) cycle (BLa), and three weeks from the end of PC (BLb).
  • The median decrease (MD) in blood lymphocytes has been calculated: MDa = BLa - basal BL; MDb = BLb - basal BL.
  • RESULTS: Of 105 patients with breast cancer 16,2% were clinical stage IIA, 19% IIB, 30,5% IIIA, 14,3% IIIB, 15,2% IIIC.
  • The complete pathologic response (pCR) rate was 14,9% in primary tumor, and 37,9% in axillary nodes.
  • Disease-free survival: (DFS) 21,8 mo (range 5 - 80.3).
  • A decrease on BL just before second AC cycle (> MDa=300 10<sup>6</sup>/L) is correlated with worse DFS, in univariant and multivariant analysis (HR =4.022; 95% CI:1.105-14.63; p 0.035 at first; HR=5.36; 95% CI:1.1-25.82; p 0.037 at former).
  • Patients with BL decrease three weeks after finishing PC (>MDb=700 10<sup>6</sup>/L) have worse DFS in univariant as multivariant analysis (HR=5.9 95% CI:1.2-27.5; p0.022 at first; HR=9.7 95% CI:1.11- 85.07; p 0.04 at former).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964682.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Fischbach NA, Spigel D, Brahmer J, Garst J, Robles R, Chung C, Wang L, Sing A, Lynch T, ARIES Investigators: Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol; 2009 May 20;27(15_suppl):8040

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary safety and effectiveness of bevacizumab (BV) based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: A bevacizumab (BV) treatment observational cohort study (OCS).
  • To further define clinical outcomes associated with BV treatment among a broader population of NSCLC pts in a real-world setting, the ARIES OCS was initiated.
  • Pt populations in OCSs are often more reflective of pts encountered in practice, permitting examination of treatment benefit and toxicity in subgroups that might be too small for study in traditional randomized controlled trials (RCTs).
  • The NSCLC cohort in ARIES will assess clinical outcomes in the overall cohort as well as subpopulations such as the elderly, pts with poor PS or pts on concurrent anticoagulants (AC).
  • Data is collected at baseline (BL) then quarterly, including targeted adverse events (AEs) and BV-related serious AEs.
  • Clinical outcomes will be descriptively summarized by baseline characteristics.
  • Key BL characteristics: 20% ≥75 yrs; 67% adenocarcinoma; 10% ECOG ≥2; 8% brain metastasis; 5% therapeutic AC.
  • CONCLUSIONS: The safety of BV in subpopulations of pts in ARIES (elderly pts, pts with ECOG PS ≥2, with brain mets at BL, or on therapeutic AC) is generally consistent with safety results from RCTs.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962849.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Boige V, Baey C, Dromain C, Ducreux M, Malka D, Pignon J, Farace F: Circulating endothelial cells (CEC) and angiogenic proteins monitoring in patients (pts) with advanced hepatocellular carcinoma (HCC) treated with bevacizumab. J Clin Oncol; 2009 May 20;27(15_suppl):4597

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CEC and serum proteins (MMP2, MMP9, VEGF, sVEGFR2, IL6, IL8, and PIGF) levels were monitored at baseline (BL) and on days (D) 3, D15 and D60 after beginning of bevacizumab therapy, and correlated with tumor response and survival.
  • Among the 38 pts evaluable for efficacy, 6 (16%) had confirmed partial response (PR), and 18 (47%) had stable disease (SD); 16 weeks disease control rate was 42%.
  • BL CEC levels (n=36 pts; median, 14/mL; range, 0-71) were not correlated with tumor size, progression-free survival (PFS), and overall survival (OS), but were higher in pts with PR or SD compared with PD (p=0.02).
  • BL IL8 levels superior to median value (n=43 pts, 80 pg/ml) were significantly correlated with shorter PFS and OS (p=0.03, p=0.04, respectively).
  • CONCLUSIONS: These results suggest that BL CEC levels might be a useful biomarker to predict bevacizumab antitumor activity and that IL8 might have a strong prognostic value in patients with advanced HCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963111.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Spigel DR, Shah C, Lorigan P, McNally R, Renschler M, Oliver J: Amrubicin (AMR) and cardiotoxicity in second-line treatment of small cell lung cancer (SCLC): A pooled analysis of left ventricular ejection fraction (LVEF) in two phase II trials. J Clin Oncol; 2009 May 20;27(15_suppl):e19019

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amrubicin (AMR) and cardiotoxicity in second-line treatment of small cell lung cancer (SCLC): A pooled analysis of left ventricular ejection fraction (LVEF) in two phase II trials.
  • Pts with measurable disease, ECOG PS 0-2, LVEF ≥50%, and prior platinum-based treatment were assessed at baseline (BL), cycles 3, 6, then every 2 cycles, and end of treatment.
  • Median age was 63 years and median BL LVEF was 60%.
  • One had BL LVEF of 85%, then 60% at cycle 3, and 70% subsequently with ongoing therapy.
  • The second, with a history of cardiomegaly, had LVEF of 55% at BL, cycle 3, and 5 by ECHO, and 29% at the time of progression after cycle 9 (cumulative AMR dose 840 mg/m<sup>2</sup>) by MUGA.
  • The patient died due to progressive disease with no evidence of CHF.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962591.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Kosty MP, Kumar P, Wozniak A, Jahanzeb M, Chung C, Wang L, Sing A, Lynch T, ARIES Investigators: Development of cavitation while on bevacizumab (BV) therapy in patients (pts) with non-small cell lung cancer (NSCLC): Results from ARIES-A bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol; 2009 May 20;27(15_suppl):e19045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of cavitation while on bevacizumab (BV) therapy in patients (pts) with non-small cell lung cancer (NSCLC): Results from ARIES-A bevacizumab (BV) treatment observational cohort study (OCS).
  • Potential risk factors include squamous histology, prior history of hemoptysis, and presence of tumor cavitation.
  • Rates of baseline (BL) cavitation in NSCLC pts and development of cavitation on BV therapy are unknown.
  • Pts in ARIES, an OCS of approximately 2,000 pts with NSCLC, had BL scans assessed for tumor cavitation.
  • For the entire ARIES population, any pt developing sPH is assessed for tumor cavitation.
  • METHODS: Pts at specified ARIES sites submitted on-treatment CT scans to an independent review facility (IRF), in addition to BL scans.
  • Evaluable pts had measurable disease at BL and at least one-post-BL scan.
  • Correlations between cavitation (pre-existing or developing on-study) and clinical, tumor and treatment characteristics are evaluated using a chi-squared test or t-test.
  • RESULTS: As of 9/15/08, 210 pts had a post-BL CT scan reviewed by the IRF.
  • Of these pts, 171 had measurable tumors at BL.
  • Key BL characteristics for the substudy and overall cohorts, respectively, include: 44% vs 51% ≥65 yrs; 67% vs 67% adenocarcinoma; 6% vs 5% therapeutic AC.
  • BL radiographic features: 41% vs 39% presence of central tumor; 13% vs 15% presence of cavitation.
  • Whether cavitation (BL or developing on-treatment) is associated with an increased risk of sPH has not been defined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962105.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Lau KF: Time dependence of prognostic values of gene-expression signatures for breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):11085

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HRs of Luminal B (LB), Basal-like (BL), HER2/ER- (HER2), Normal-like (NL) vs. Luminal A (LA) of Intrinsic Subtypes were 6.8 (4.0-11.5), 5.7 (3.2-10.0), 7.6 (4.0-14.1) and 1.7 (0.9-3.3) at yr 2.
  • Concordance rates of RS and SVP were 1.0, 0.91, 0.86, 0.72 and 0.62 for BL, HER2, LB, LA, NL of Intrinsic Subtypes.
  • Concordance between RS and SPV is highest in the basal-like tumors and lowest in the Luminal B and Normal-like subtypes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963175.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Zarski JP: [Epidemiology of chronic hepatitis B]. Presse Med; 2006 Feb;35(2 Pt 2):304-7
Genetic Alliance. consumer health - Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Epidémiologie de l'hépatite chronique B.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493334.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Surface Antigens; EC 2.6.1.- / Transaminases
  • [Number-of-references] 12
  •  go-up   go-down


42. Ajana F: [Hepatitis B virus still under debate]. Arch Pediatr; 2006 Sep;13(9):1269-74
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatitis B virus still under debate].
  • [Transliterated title] L'hépatite virale B, encore et toujours d'actualité.
  • Hepatitis B is the most known viral hepatitis, and often turns into a media event in France.
  • Its prevalence and incidence depend on countries, regions, and their inhabitants.
  • The virus is highly infectious with a high genomic variability.
  • Its immune reaction and pathology seem complex, but the latest consensus conferences gave a practical management.
  • If Papillomavirus vaccine is ready and coming soon as the second STD vaccine, hepatitis B vaccine is available since 1982, and used with a real success.
  • Fighting hepatitis B is to continue all together to immunize children and babies born from infected mothers, to adopt universal health workers precautions, to educate and modify high risk behaviours, to treat and prevent hepatitis B complications and superinfections, and finally to monitor and detect any resistant hepatitis B strain.
  • [MeSH-major] Hepatitis B / prevention & control. Hepatitis B / transmission
  • [MeSH-minor] Hepatitis B Vaccines / administration & dosage. Humans

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16920340.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Number-of-references] 12
  •  go-up   go-down


43. Stepień M, Czarkowski MP: [Hepatitis B in Poland in 2008]. Przegl Epidemiol; 2010;64(2):239-44
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In total number of registered hepatitis B cases 19.6% were acute ones (incidence 0.69; regionally ranged from 0.30 in zachodniopomorskie to 1.01 in małopolskie) and chronic hepatitis accounted for 80.4% of all cases (incidence 2.82 per 100,000).
  • The registered acute hepatitis B incidence was 28% lower than in 2007 and decrease of this rate, more than 20% per year, was observed since 2005.
  • Unlike acute, new chronic hepatitis B incidence was similar to that reported in previous years, and this situation seems to be fixed.
  • The highest reported incidence (both acute and chronic) was observed in age groups 35-39 years old (5.61) and 15-19 (5.59).
  • Acute hepatitis B incidence demonstrated three peaks: at the age 25-29 (1.03); at the age 35-39 (1.03) and at 75 and over (1.16).
  • In contrast, the highest incidence of chronic type was in one age group only: 15-19 (5.25 per 100,000).
  • Overall the most affected groups were young adult, but age distribution varied in relation to sex and to the type of residence.
  • Approximately 96.9% of acute hepatitis B and 75.3% of chronic cases were hospitalized in 2008 in Poland.
  • 68 people died of hepatitis B, including 49 of chronic and 19 of acute hepatitis B.
  • [MeSH-major] Disease Outbreaks / statistics & numerical data. Hepatitis B / epidemiology. Hepatitis B Vaccines / administration & dosage. Registries / statistics & numerical data

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20731229.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


44. Rosińska M, Czarkowski MP: [Hepatitis B in Poland in 2007]. Przegl Epidemiol; 2009;63(2):245-50
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In Poland in 2007 there were registered 1,454 cases of hepatitis B (incidence 3.81 per 100,000 population), including 364 acute cases (incidence 0.95 per 100,000).
  • Acute cases are registered separately beginning in 2005 and since then a decrease of acute hepatitis B incidence of more then 20% per year was observed in contrast to stable epidemiological situation regarding chronic hepatitis B.
  • Total hepatitis B incidence varied across the regions form 1.12 in warminsko-mazurskie to 7.26 per 100,000 in lodzkie and acute hepatitis B incidence from 0.30 in zachodniopomorskie to 1.51 in podlaskie.
  • In contrast acute hepatitis B incidence demonstrated two peaks: at the age 25-29 (1.46) and at the age 65 and over (in the age groups 65-74 and 75+ respectively 1.64 and 1.77).
  • Acute hepatitis B was over two times as frequent among men then women (incidence 1.30 and 0.63 respectively) and more frequent in the urban then in the rural areas (incidence 1.01 and 0.87 respectively).
  • However, age distribution differed in relation to sex (incidence had two peaks in men--age groups 25-29 and 75+ and increased constantly with age in women) and to the type of residence (incidence was the highest among people aged 25--49 in cities and among people aged 60 or more in rural areas).
  • In 2007 97,8% of acute hepatitis B and 67,8% of chronic cases were hospitalized.
  • 72 people died of hepatitis B, including 15 people of acute hepatitis B.
  • [MeSH-major] Disease Outbreaks / statistics & numerical data. Hepatitis B / epidemiology

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799254.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


45. Ergünay K: [Occult hepatitis B infection]. Mikrobiyol Bul; 2005 Apr;39(2):241-9
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Occult (silent, inapparent) hepatitis B infection is defined as the presence of HBV-DNA where hepatitis B virus (HBV) surface antigen (HBsAg) is absent, outside of acute hepatitis window period.
  • The mechanism, clinical outcome and risk of transmission of occult hepatitis B is not yet clearly defined.
  • In this review article, the importance of occult hepatitis B infection has been discussed with a focus on pathogenesis, clinical significance and diagnostic laboratory methods.
  • [MeSH-major] Hepatitis B / diagnosis. Hepatitis B virus / isolation & purification

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16128037.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Surface Antigens
  • [Number-of-references] 12
  •  go-up   go-down


46. Thimme R, Blum HE: [Therapy of hepatitis B]. Praxis (Bern 1994); 2006 Sep 6;95(36):1383-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Worldwide, there are approximately 350 million carriers of hepatitis B virus (HBV), of whom half a million to 1 million die from liver disease.
  • The efficacy ot the respective antivirals is affected by virological and clinical parameters, thus requiring individual treatment strategies that will be discussed in detail.
  • [MeSH-minor] Adenine / administration & dosage. Adenine / analogs & derivatives. Adenine / therapeutic use. Administration, Oral. Antiviral Agents / administration & dosage. Antiviral Agents / therapeutic use. Diagnosis, Differential. Humans. Immunologic Factors / administration & dosage. Immunologic Factors / therapeutic use. Interferon-alpha / administration & dosage. Interferon-alpha / therapeutic use. Lamivudine / administration & dosage. Lamivudine / therapeutic use. Organophosphonates / administration & dosage. Organophosphonates / therapeutic use. Reverse Transcriptase Inhibitors / administration & dosage. Reverse Transcriptase Inhibitors / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Adefovir .
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16989181.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine; 6GQP90I798 / adefovir; JAC85A2161 / Adenine
  • [Number-of-references] 24
  •  go-up   go-down


47. Bradarić N, Pavić I, Kuzmicić N, Bradarić I: [Hepatitis B: who should be treated?]. Acta Med Croatica; 2009 Dec;63(5):385-9
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Modifications in therapeutic indications for both acute and chronic hepatitis B presented below are based on standings of the Consensus Conference of the American National Institutes of Health (NIH) from 2008, Canadian Consensus Conference from 2007, and Consensus Conference of the European Association for the Study of the Liver (EASL) from 2009.
  • [MeSH-minor] Acute Disease. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / therapy. Humans

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20198896.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


48. Kuszewski K: [Hepatitis B in Poland in 2003]. Przegl Epidemiol; 2005;59(2):297-301
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatitis B in Poland in 2003].
  • [Transliterated title] Wirusowe zapalenie watroby typu B w 2003 roku.
  • In 2003 1,812 cases of hepatitis B were registered in Poland, including 118 (6.5%) caused by mixed infections with HBV and HCV.
  • The incidence was 4.7 per 100,000.
  • Compared to the preceding year, the number of cases decreased by 209 cases and the incidence decreased by 0.6 per 100,000.
  • The decreasing trend of HBV continued during the recent years.
  • During the consecutive years of hepatitis B control programme implementation the incidence decreased below 5.0 per 100,000 becoming comparable to the European level.
  • [MeSH-major] Hepatitis B / epidemiology. Hepatitis B / prevention & control
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Hepatitis B Vaccines / administration & dosage. Hospitalization / statistics & numerical data. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Poland / epidemiology. Risk Factors. Rural Population / statistics & numerical data. Sex Distribution. Urban Population / statistics & numerical data

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16190533.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


49. Magdzik W, Czarkowski MP: [Epidemiological situation of hepatitis B in Poland in the years 1979-2004]. Przegl Epidemiol; 2006;60(3):471-80
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Disease Outbreaks / statistics & numerical data. Hepatitis B / epidemiology

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17249168.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


50. Fittler A, Matus Z, Kocsis B, Botz L: [Chemical and microbiological aspects of the quantitative analysis of amphotericin B]. Acta Pharm Hung; 2008;78(3):95-102
Hazardous Substances Data Bank. AMPHOTERICIN B .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemical and microbiological aspects of the quantitative analysis of amphotericin B].
  • [Transliterated title] Amfotericin B tartalmú készítmények kvantitatív analízisének kémiai és mikrobiológiai vonatkozásai.
  • Amphotericin B can be determined by chemical (HPLC, spectrophotometry) and microbiological (bioassay) methods.
  • The utilization of both during a stability test can give more detailed information about the activity and concentration change of amphotericin B solutions.
  • Previously published HPLC methods do not lay stress on the separation of by-constituents present in the substance.
  • We have also observed that the bioassay conditions described in the Ph. Eur.
  • 6. are not suitable for the measurement of concentration change experienced during a stability test.
  • The aim of our study was to optimize the chemical and microbiological methods.
  • We have improved the eluent system based on earlier HPLC methods for the separation of the main heptaene and the minor tetraene by-constituents in Fungizone (Bristol-Myers Squibb).
  • The most optimal bioassay conditions were determined where a relatively wide concentration range can be measured.
  • With the improved methods both chemical and microbiological changes can be more accurately measured in our future stability tests.
  • [MeSH-major] Amphotericin B / analysis. Antifungal Agents / analysis
  • [MeSH-minor] Chromatography, High Pressure Liquid. Drug Stability. Humans. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18986086.001).
  • [ISSN] 0001-6659
  • [Journal-full-title] Acta pharmaceutica Hungarica
  • [ISO-abbreviation] Acta Pharm Hung
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


51. Pavić I: [Hepatitis B: who should be treated?]. Acta Med Croatica; 2005;59(5):419-21
MedlinePlus Health Information. consumer health - Hepatitis C.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment is also recommended for immunocompromised patients and those older than 60 years with acute HBV infection.
  • The patient's age, severity of liver disease, likelihood of response and possibility of adverse effects and complications should be considered before deciding on treatment.
  • [MeSH-minor] Acute Disease. HIV Infections / complications. Hepatitis C, Chronic / drug therapy. Hepatitis C, Chronic / immunology. Hepatitis C, Chronic / virology. Hepatitis D / complications. Humans. Liver Cirrhosis / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381237.001).
  • [ISSN] 1330-0164
  • [Journal-full-title] Acta medica Croatica : c̆asopis Hravatske akademije medicinskih znanosti
  • [ISO-abbreviation] Acta Med Croatica
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


52. Bagnato B, Marino MG, Ruggiero F, Zaratti L, Franco E: [Persistence of protection induced by hepatitis B vaccine.]. Ig Sanita Pubbl; 2009 Nov-Dec;65(6):657-70
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Persistence of protection induced by hepatitis B vaccine.].
  • [Transliterated title] Persistenza della protezione indotta dal vaccino anti-epatite B.
  • Universal mass vaccination against hepatitis B virus in infants and adolescents, together with targeted prophylaxis for risk groups, is recommended since almost twenty years all over the world to prevent infection and related diseases.
  • Safety and effectiveness of the vaccine have been clearly demonstrated while unambiguous data about long term protection and need of booster administration are not yet available, especially for high risk subjects like health care workers and dialysis patients.
  • By means of new vaccines and new adjuvants better results could be obtained in a next future.
  • [MeSH-major] Hepatitis B. Hepatitis B Vaccines
  • [MeSH-minor] Health Personnel. Humans. Immunization, Secondary

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20376163.001).
  • [ISSN] 0019-1639
  • [Journal-full-title] Igiene e sanità pubblica
  • [ISO-abbreviation] Ig Sanita Pubbl
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


53. Czarkowski MP, Bobel D: [Hepatitis B in Poland in 2006]. Przegl Epidemiol; 2008;62(2):317-24
MedlinePlus Health Information. consumer health - Rural Health Concerns.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In total number of registered cases 70% were new chronic ones (incidence 3.1 per 100,000; regionally ranged from 0.4 in podlaskie voivodeship to 8.8 in łódzkie), and only 30% acute cases (incidence 1.3; regionally ranged from 0.6 in zachodniopomorskie voivodeship to 2.1 in slaskie).
  • The highest reported incidence (both acute and chronic) was observed in age group 35-39 years (6.3 per 100,000) but the highest incidence of chronic form was among 15-19 (4.8) years old and acute form among 60-64 years old (2.4).
  • There were 64 deaths attributed to hepatitis B in 2006 including 8 deaths of acute and 56 of chronic hepatitis B.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807474.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


54. Degos F: [Vaccination against hepatitis B virus]. Presse Med; 2006 Feb;35(2 Pt 2):347-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / prevention & control. Family Practice. Female. France. Humans. Infant, Newborn. Infectious Disease Transmission, Vertical. Liver Neoplasms / etiology. Liver Neoplasms / prevention & control. Male. Pregnancy. Risk Factors

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Immunization.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493339.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  • [Number-of-references] 32
  •  go-up   go-down


55. Chirife AM, Bilbao ER, Giménez L, Marino L: [Cutaneous B cell processes with nodular pattern]. Medicina (B Aires); 2006;66(4):307-12
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous B cell processes with nodular pattern].
  • Cutaneous lymphomas are low grade malignant neoplasms with favourable prognosis.
  • Those related to the germinal centre with nodular pattern may be: follicular lymphomas (LFC) or extranodal marginal zone B-cell lymphomas (LMC).
  • The objective of this study was to check the incidence and the value of both histology and immunohistochemistry in differential diagnosis.
  • Fifty six patients with cutaneous lymphomas were selected within the period 1995-2004.
  • Thirty two out of the fifty six cutaneous lymphoid infiltrates were of T origin (57.1%) and twenty four of B origin (42.8%), ten out of this last figure (17.7%) were lymphoid processes with nodular pattern Four LFC, three LMC and three HLC were diagnosed.
  • We conclude that lymphoid B cell processes with nodular pattern are unusual.
  • Histology and immunohistochemistry proved to be useful in the differential diagnosis of these lymphomas, and for differentiating these from lymphoid hyperplasias or non tumoral hyperplasias.
  • [MeSH-major] Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Follicular / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Biopsy. Diagnosis, Differential. Female. Flow Cytometry. Germinal Center / chemistry. Germinal Center / pathology. Humans. Hyperplasia / pathology. Male. Middle Aged. Neprilysin / analysis. Polymerase Chain Reaction. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977965.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


56. von Weizsäcker F: [Management of chronic hepatitis B]. Praxis (Bern 1994); 2005 Apr 20;94(16):649-52
Hazardous Substances Data Bank. LAMIVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a leading cause of liver cirrhosis and hepatocellular carcinoma, chronic hepatitis B poses a major health care problem.
  • Efficacy of the respective antivirals is affected by virological and clinical parameters, thus requiring individual treatment strategies.

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. Adefovir .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900829.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 2T8Q726O95 / Lamivudine; 30IQX730WE / Polyethylene Glycols; 6GQP90I798 / adefovir; 76543-88-9 / interferon alfa-2a; JAC85A2161 / Adenine
  • [Number-of-references] 14
  •  go-up   go-down


57. Czarkowski MP, Rosińska M: [Hepatitis B in Poland in 2005]. Przegl Epidemiol; 2007;61(2):273-9
MedlinePlus Health Information. consumer health - Rural Health Concerns.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic hepatitis accounted for 62% of all cases (incidence 2.8 per 100,000) and acute hepatitis for 38% (incidence 1.7).
  • 85 deaths from hepatitis B were registered in 2005, including 62 from chronic and 23 from acute hepatitis B.

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956042.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


58. Roll P, Tony HP: [B-cell-targeted therapy in the treatment of autoimmune diseases]. Z Rheumatol; 2009 May;68(3):255-9
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [B-cell-targeted therapy in the treatment of autoimmune diseases].
  • [Transliterated title] B-Zell-gerichtete Therapie bei Autoimmunerkrankungen.
  • In particular, the introduction of rituximab, a depleting antibody targeting CD20+ B cells and its clinical efficacy in rheumatoid arthritis, systemic lupus erythematosus, vasculitis and multiple sclerosis has stimulated further B-cell-targeted therapies.
  • Other biologicals targeting CD20 are under clinical investigation.
  • New strategies include targeting further B-cell surface markers such as CD22, as well as blocking B-cell-activating factors or their receptors.
  • [MeSH-minor] Animals. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Biological Products / adverse effects. Biological Products / therapeutic use. Clinical Trials as Topic. Humans. Lymphocyte Count. Lymphotoxin-alpha / antagonists & inhibitors. Rituximab. Sialic Acid Binding Ig-like Lectin 2 / immunology. Toll-Like Receptors / antagonists & inhibitors. Treatment Outcome

  • Genetic Alliance. consumer health - Autoimmune Diseases.
  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2008 Jul;67(7):917-25 [17965121.001]
  • [Cites] Arthritis Rheum. 2008 Jan;58(1):61-72 [18163485.001]
  • [Cites] Arthritis Rheum. 2005 Mar;52(3):710-21 [15751074.001]
  • [Cites] Ther Clin Risk Manag. 2007 Oct;3(5):953-9 [18473018.001]
  • [Cites] Semin Immunol. 2006 Oct;18(5):305-17 [16916610.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):817-26 [15634903.001]
  • [Cites] Arthritis Rheum. 2008 Sep;58(9):2652-61 [18759293.001]
  • (PMID = 19384549.001).
  • [ISSN] 0340-1855
  • [Journal-full-title] Zeitschrift fur Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antirheumatic Agents; 0 / Biological Products; 0 / Lymphotoxin-alpha; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / Toll-Like Receptors; 4F4X42SYQ6 / Rituximab; 73B0K5S26A / belimumab
  • [Number-of-references] 12
  •  go-up   go-down


59. Ott MM, Müller-Hermelink HK: [Splenic marginal zone B cell lymphomas]. Pathologe; 2008 Mar;29(2):143-7
Genetic Alliance. consumer health - B-Cell Lymphomas.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic marginal zone B cell lymphomas].
  • [Transliterated title] Splenische Marginalzonen-B-Zell-Lymphome.
  • Splenic marginal zone B cell lymphomas (SMZBCL) are rare, organotypic, lymphoid neoplasms with distinct clinicopathological features.
  • Molecularly, somatic hypermutation of IgVH genes can be detected in roughly half of the cases, and deletions in 7q are present in 45% of tumors.
  • This association underlines the importance of antigenic stimulation in the proliferation of the tumor cells in HCV-associated SMBCL, if not also in their classical counterparts.
  • More recently, gene profiling studies using cDNA microarrays revealed a homogeneous expression profile in SMZBCL, thus further confirming the notion of a distinct tumor entity.
  • The clinical course is indolent in the majority of cases; however, some patients follow a more aggressive clinical course, usually associated with some particular molecular features in these tumors, such as unmutated IgVH genes and 7q deletions.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Antigens, CD / analysis. Chromosomes, Human, Pair 18. Chromosomes, Human, Pair 3. Chromosomes, Human, Pair 5. Chromosomes, Human, Pair 9. Cytogenetics. Diagnosis, Differential. Humans. Immunophenotyping. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, B-Cell, Marginal Zone / pathology. Molecular Biology. Trisomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jun 15;107(12):4643-9 [16493005.001]
  • [Cites] Am J Surg Pathol. 1997 Jul;21(7):772-80 [9236833.001]
  • [Cites] Histopathology. 2002 Jan;40(1):22-30 [11903595.001]
  • [Cites] Blood. 2005 Jan 1;105(1):74-6 [15353484.001]
  • [Cites] Eur J Haematol. 2006 May;76(5):392-8 [16480431.001]
  • [Cites] Oncogene. 1999 Nov 4;18(46):6271-7 [10597225.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2727-37 [14630827.001]
  • [Cites] Am J Pathol. 2001 May;158(5):1843-50 [11337382.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2837-44 [11675358.001]
  • [Cites] Histopathology. 1996 Dec;29(6):571-5 [8971565.001]
  • [Cites] Blood. 1994 Dec 1;84(11):3828-34 [7949139.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1583-9 [10329610.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):380-6 [10862046.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Jan 15;156(2):122-8 [15642391.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):455-66 [1599024.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1299-304 [11830479.001]
  • [Cites] Leukemia. 2001 Apr;15(4):628-34 [11368366.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Clin Lymphoma. 2005 Mar;5(4):241-5 [15794856.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3034-44 [16397126.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1831-8 [15914563.001]
  • [Cites] Immunol Today. 1998 Sep;19(9):421-6 [9745206.001]
  • [Cites] Histopathology. 1998 Sep;33(3):230-9 [9777389.001]
  • [Cites] Lancet. 2004 Jun 5;363(9424):1869-70 [15183626.001]
  • [Cites] Hum Pathol. 1989 Dec;20(12):1225-7 [2591956.001]
  • (PMID = 18214486.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


60. Mikołuć B, Piotrowska-Depta M, Pietrucha B, Bernatowska E: [Haemophilus influenzae type b--active prevention]. Med Wieku Rozwoj; 2008 Apr-Jun;12(2 Pt 2):661-5
MedlinePlus Health Information. consumer health - Haemophilus Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Haemophilus influenzae type b--active prevention].
  • Infection with non-encapsulated types of Haemophilus influenzae bacteria can cause such diseases as sinusitis, pharyngitis, bronchitis or otitis.
  • Of the six capsulated types of Haemophilus influenzae, type b (Hib) is the main cause of invasive diseases in childhood, including meningitis, septicaemia, epiglottitis, pneumonia, arthritis, osteomyelitis.
  • [MeSH-major] Haemophilus Infections / prevention & control. Haemophilus Vaccines / administration & dosage. Haemophilus influenzae type b / immunology

  • Genetic Alliance. consumer health - Haemophilus Influenzae.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418941.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Haemophilus Vaccines
  • [Number-of-references] 42
  •  go-up   go-down


61. Nagel A, Hertl M, Eming R: [B-cell-depleting antibodies in skin diseases]. Hautarzt; 2008 Oct;59(10):793-805
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [B-cell-depleting antibodies in skin diseases].
  • [Transliterated title] Einsatz B-Zell-depletierender Antikörper bei Hauterkrankungen.
  • The remarkable clinical improvement seen in patients with rheumatoid arthritis after treatment with the monoclonal anti-CD20 antibody, rituximab, has strongly augmented the interest in B-cell-targeted therapies in different autoimmune diseases.
  • Future clinical and immunological investigations are mandatory to precisely define the contribution of impaired B-cell function in development and progression of autoimmune mediated skin disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Rheum Dis. 2007 Jun;66(6):818-20 [17148544.001]
  • [Cites] J Allergy Clin Immunol. 2003 Apr;111(4):697-703 [12704346.001]
  • [Cites] Arthritis Rheum. 2006 Aug;54(8):2377-86 [16869000.001]
  • [Cites] Ann Rheum Dis. 2007 Mar;66(3):351-7 [16950808.001]
  • [Cites] Ann Rheum Dis. 2008 Jul;67(7):917-25 [17965121.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1050:34-9 [16014518.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jul;5(7):564-76 [16816838.001]
  • [Cites] Eur J Immunol. 2008 Jan;38(1):292-8 [18085668.001]
  • [Cites] J Allergy Clin Immunol. 2008 Jan;121(1):122-8 [18206507.001]
  • [Cites] Clin Immunol. 2007 Apr;123(1):66-73 [17275413.001]
  • [Cites] Curr Opin Immunol. 2007 Jun;19(3):327-36 [17433868.001]
  • [Cites] Arthritis Rheum. 2007 May;56(5):1464-77 [17469105.001]
  • [Cites] N Engl J Med. 2007 Aug 9;357(6):545-52 [17687130.001]
  • [Cites] Br J Dermatol. 2005 Sep;153(3):620-5 [16120153.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6(5):366-73 [18201220.001]
  • [Cites] Arthritis Rheum. 2007 Mar;56(3):772-8 [17328049.001]
  • [Cites] Eur J Immunol. 2002 Mar;32(3):627-33 [11857336.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):817-26 [15634903.001]
  • [Cites] J Clin Invest. 2005 Nov;115(11):3083-92 [16239971.001]
  • [Cites] J Invest Dermatol. 2008 Dec;128(12):2850-8 [18563178.001]
  • [Cites] Br J Dermatol. 2006 Aug;155(2):330-6 [16882171.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):192-201 [16385515.001]
  • [Cites] Blood. 2008 Aug 15;112(4):1147-50 [18375792.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1772-9 [17065638.001]
  • [Cites] Arthritis Res Ther. 2006;8(6):R167 [17092341.001]
  • [Cites] Exp Dermatol. 2007 Feb;16(2):87-93 [17222220.001]
  • [Cites] J Invest Dermatol. 2006 Dec;126(12):2621-30 [16841036.001]
  • [Cites] Arthritis Res Ther. 2006;8(4):R129 [16859536.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):717-9 [8642274.001]
  • [Cites] Arthritis Rheum. 2006 Feb;54(2):613-20 [16447239.001]
  • [Cites] J Clin Invest. 2006 May;116(5):1159-66 [16670756.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20878-83 [18093919.001]
  • [Cites] Immunity. 2004 May;20(5):517-27 [15142521.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):703-11 [15738055.001]
  • [Cites] Clin Immunol. 2007 Jan;122(1):62-74 [17046329.001]
  • [Cites] Immunity. 2004 Jun;20(6):785-98 [15189742.001]
  • (PMID = 18779943.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies
  • [Number-of-references] 36
  •  go-up   go-down


62. Gekas J, Broermann L, Heidenreich W: [Outcome of pregnancy in patients with haemophilia B--two case reports]. Z Geburtshilfe Neonatol; 2007 Apr;211(2):90-2
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Haemophilia B is a congenital coagulation disorder with a low activity of the coagulation factor IX.
  • Both for mother and the child, who has potentially inherited the disorder, there is a dramatically increased tendency for bleeding with the potential for developing further complications.

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486531.001).
  • [ISSN] 0948-2393
  • [Journal-full-title] Zeitschrift für Geburtshilfe und Neonatologie
  • [ISO-abbreviation] Z Geburtshilfe Neonatol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Blood Coagulation Factors; 37224-63-8 / prothrombin complex concentrates; 94ZLA3W45F / Arginine
  •  go-up   go-down


63. Pierzyńskii P, Urban R, Laudański T, Urban J: [B lynch suture for post partum heamorrhage due to uterine atony]. Ginekol Pol; 2006 Feb;77(2):146-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [B lynch suture for post partum heamorrhage due to uterine atony].
  • [Transliterated title] Zastosowanie szwu lyncha typu b w leczeniu krwotoku poporodowego w przebiegu atonii macicy.
  • Uterine atony and concomittant massive haemorrhage is one of the most dangerous complications of labour.
  • Conventional, conservative treatment approach comprising of oxytocics such as oxytocin, methergin or prostaglandins may fail in some cases, mandating surgical techniques, including hysterectomy.
  • B Lynch compression uterine suture may be a safe and effective method of treatment in post partum heamorrhage and in most of cases may replace more complicated techniques.
  • In this article, together with referring the technical aspects of this procedure, we present a case of successful treatment.
  • [MeSH-major] Postpartum Hemorrhage / surgery. Suture Techniques. Uterine Inertia / surgery. Uterus / surgery
  • [MeSH-minor] Adult. Female. Hemostasis, Surgical / methods. Humans. Infant, Newborn. Pregnancy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16736973.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


64. Duca E, Manole A, Hurmuzache M, Ivan A: [Epidemiology of viral hepatitis B in the Iasi County in the interval 1990-2005]. Rev Med Chir Soc Med Nat Iasi; 2006 Oct-Dec;110(4):987-92
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As a result of the preventive interventions, in the interval 1996-2005, the morbidity from HVB was lower in all age groups as compared to the interval 1990-1995.
  • The significant decrease in morbidity following the introduction of a vaccination program and the preservation of a constantly descending trend reflect the favourable change in the epidemiological process of HVB.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438913.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


65. Grzegorzewska AE, Kurzawska-Firlej D, Swiderski A, de Mezer-Dambek M, Frankiewicz D, Zaremba-Drobnik D, Banachowicz W, Dumanowska-Zmuda A, Ratajewski W, Niepolski L, Krawczyk R, Sobolewski J, Pulchny J, Molenda J, Wojciechowski J, Mikstacki Z, Zachwieja J: [Infections with hepatitis B virus in hemodialysis units of Wielkopolska]. Przegl Epidemiol; 2008;62(1):29-37
MedlinePlus Health Information. consumer health - Kidney Failure.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients (10.3%) showed symptoms of acute hepatitis.
  • CONCLUSIONS: HBV infection in patients with chronic kidney disease is most frequently detected before or due to initiation of IHD treatment.
  • [MeSH-major] Hemodialysis Units, Hospital / statistics & numerical data. Hepatitis B / diagnosis. Hepatitis B / epidemiology. Hepatitis B Antigens / blood. Kidney Failure, Chronic / epidemiology. Kidney Failure, Chronic / therapy. Renal Dialysis / statistics & numerical data

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536222.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Hepatitis B Antigens; 0 / Hepatitis B Core Antigens; 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B Vaccines
  •  go-up   go-down


66. Açikgöz ZC, Gamberzade S, Göçer S, Ceylan P: [Inhibitor effect of vaginal lactobacilli on group B streptococci]. Mikrobiyol Bul; 2005 Jan;39(1):17-23
MedlinePlus Health Information. consumer health - Streptococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, the in vitro inhibitory effects of 51 lactobacilli (of them 50 were purified from vaginal swabs, 1 from a commercial vaginal tablet) on five GBS (4 clinical isolates and 1 standard strain) were investigated by sandwich plate technique and deferred antagonism well technique.
  • Ten clinical isolates (20%) and the drug-purified Lactobacilli expressed pronounced inhibitory effects on growth of GBS.
  • All of the inhibitory isolates and 10 randomly selected non-inhibitory isolates were identified by API 50CHL kit (BioMeriéx, France).
  • Seven (70%) of the inhibitory clinical isolates were Lactobacillus rhamnosus.
  • The inhibitory isolates had higher acid production than the non-inhibitory ones (p < 0.05), and pH-adjustment destroyed their inhibitory effects entirely.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900833.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


67. Asselah T, Castelnau C, Marcellin P: [Treatment of chronic hepatitis B]. Presse Med; 2006 Feb;35(2 Pt 2):327-34
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Traitement de l'hépatite chronique B.

  • Genetic Alliance. consumer health - Hepatitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Adefovir .
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16493337.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Recombinant Proteins; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine; 30IQX730WE / Polyethylene Glycols; 47RRR83SK7 / interferon alfa-2a; 5968Y6H45M / entecavir; 5Z93L87A1R / Guanine; 6GQP90I798 / adefovir; 9008-11-1 / Interferons; JAC85A2161 / Adenine; Q46947FE7K / peginterferon alfa-2a
  • [Number-of-references] 40
  •  go-up   go-down


68. Kociszewska-Najman B, Oslislo A, Szymusik I, Pietrzak B, Jabiry-Zieniewicz Z: [Intrapartum prophylaxis against group B Streptococcus infection--own experience]. Ginekol Pol; 2010 Dec;81(12):913-7
MedlinePlus Health Information. consumer health - Streptococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The aim of the following work was to assess the efficacy of the intrapartum antibiotic prophylaxis (IAP) of the GBS infection, together with the diagnostic and therapeutic management of the newborn, based on the type and frequency of neonatal complications in the children of GBS carriers.
  • [MeSH-major] Antibiotic Prophylaxis. Bacteremia / prevention & control. Infectious Disease Transmission, Vertical / prevention & control. Pregnancy Complications, Infectious / drug therapy. Streptococcal Infections / prevention & control. Streptococcal Infections / transmission. Streptococcus agalactiae / isolation & purification

  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21395081.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


69. Aksoy A, Ozdarendeli A: [Genotyping of hepatitis B virus by restriction enzyme analysis]. Mikrobiyol Bul; 2006 Jul;40(3):215-23
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different genotypes of the hepatitis B virus may influence the clinical outcome of the disease.
  • The RFLP assay indicated that genotype D was the only detected type in our samples.
  • In conclusion, genotype D is the predominant type among hepatitis B patients in our region.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001851.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / DNA Primers; 0 / DNA, Viral
  •  go-up   go-down


70. Szeberin Z, Firneisz G, Bíró G, Szabó GV, Sótonyi P, Windisch M, Krepuska M, Sípos F, Mihály E, Acsády G: [Surgical treatment of acute type-B aortic dissection associated with cocaine use]. Orv Hetil; 2009 Jan 18;150(3):129-31
MedlinePlus Health Information. consumer health - Cocaine.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of acute type-B aortic dissection associated with cocaine use].
  • Almost all patients in Hungary suffering from type B aortic dissection are referred to our department for treatment.
  • AIM: We introduce the case of a regular cocaine user, who suffered an acute type B aortic dissection and was treated surgically.
  • RESULTS: We performed a successful operation: acute thoracoabdominal aortic refenestration, no complication was detected.
  • CONCLUSIONS: Thoracoabdominal aortic refenestration can save the life of patients presenting with acute type B dissection.
  • [MeSH-minor] Acute Disease. Adult. Humans. Hungary / epidemiology. Magnetic Resonance Angiography. Male. Reoperation. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Aortic Aneurysm.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19129148.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


71. Altindiş M, Uslan I, Cetinkaya Z, Yüksel S, Ciftçi IH, Demirtürk N, Ozdemir M, Arslan F, Aktepe OC: [Investigation of hemodialysis patients in terms of the presence of occult hepatitis B]. Mikrobiyol Bul; 2007 Apr;41(2):227-33
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 226 HBsAg negative sera were included to the study, of which 153 were from hemodialysis patients (97 male, 56 female; mean age: 41.3 +/- 5.8 years), and 73 were from non-hemodialyzed individuals (46 male, 27 female; mean age: 36.5 +/- 6.9 years) who had serological evidence of previous HBV and HCV infections.
  • Nineteen (12.4%) of HBsAg-negative hemodialysis patients and five (6.8%) of the non-hemodialyzed subjects were found positive for HBV-DNA (viral loads were > or =10(4) copies/ml, and 10(3)-10(4) copies/ml, repectively).
  • The rates of occult HBV infection in the anti-HCV positive hemodialysis patients and anti-HCV positive non-hemodialyzed subjects were detected as 27.5% (11/40) and 2.4% (1/41), respectively.
  • [MeSH-major] Carrier State / diagnosis. DNA, Viral / analysis. Hepatitis B / diagnosis. Hepatitis B virus / genetics. Renal Dialysis. Viremia / diagnosis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682709.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Hepatitis B Antibodies; 0 / Hepatitis B Surface Antigens; 0 / Hepatitis C Antibodies
  •  go-up   go-down


72. Luczyński W, Muszyńska-Rosłan K, Krawczuk-Rybak M, Lebensztejn DM: [Immunotherapy in aplastic anaemia as a cause of reactivation of hepatitis B virus-immunologic aspects]. Wiad Lek; 2005;58(11-12):697-9
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunotherapy in aplastic anaemia as a cause of reactivation of hepatitis B virus-immunologic aspects].
  • In August 2002--admitted to Department of Pediatric Oncology due to pancytopenia--diagnosis of severe aplastic anaemia was made (bone marrow cellularity--10%).
  • He was treated with cefuroxim, acyclovir and drugs improving liver cell function, cyclosporin was stopped.
  • Presence of HBV DNA in serum confirmed HBV reactivation--a boy received lamivudine and cyclosporin again (as a maintenance therapy of aplastic anaemia).

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16594488.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antiviral Agents; 0 / Immunosuppressive Agents; 0 / Interferon-alpha; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine; 83HN0GTJ6D / Cyclosporine
  •  go-up   go-down


73. Marcellin P, Asselah T, Boyer N: [Treatment of chronic hepatitis B]. Rev Prat; 2005 Mar 31;55(6):624-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Traitement de l'hépatite chronique B.
  • A number of nucleoside analogs, with favorable toxicity profiles and a promise of increased effectiveness against HBV, are at various stages of clinical development.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15913114.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antiviral Agents
  • [Number-of-references] 45
  •  go-up   go-down


74. Flisiak R, Jaroszewicz J: [Treatment recommendations of chronic hepatitis B. Did the world escape us?]. Przegl Epidemiol; 2008;62(1):133-8
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Adenine / analogs & derivatives. Adenine / therapeutic use. Disease Management. Drug Therapy, Combination. Guanine / analogs & derivatives. Guanine / therapeutic use. Humans. Interferon-alpha / therapeutic use. Lamivudine / therapeutic use. National Health Programs / organization & administration. Organophosphonates / therapeutic use. Poland. Polyethylene Glycols / therapeutic use. Randomized Controlled Trials as Topic. Recombinant Proteins. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. Adefovir .
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18536235.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 2T8Q726O95 / Lamivudine; 30IQX730WE / Polyethylene Glycols; 5968Y6H45M / entecavir; 5Z93L87A1R / Guanine; 6GQP90I798 / adefovir; 76543-88-9 / interferon alfa-2a; JAC85A2161 / Adenine
  • [Number-of-references] 10
  •  go-up   go-down


75. Yamazhan T, Sertöz R, Pullukçu H, Taşbakan M, Ulusoy S, Erensoy S: [A case of chronic hepatitis B with primary adefovir resistance]. Mikrobiyol Bul; 2007 Apr;41(2):297-301
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of chronic hepatitis B with primary adefovir resistance].
  • [Transliterated title] Adefovire primer dirençli bir kronik B hepatiti olgusu.
  • Implementation of antiviral therapy leads to the emergence of mutant strains during the treatment in chronic hepatitis B.
  • Hepatitis B virus (HBV) with primary antiviral resistance may be rarely encountered.
  • In this report, a chronic hepatitis B case who had never received adefovir dipivoxil but had primary adefovir resistance, was presented.
  • HBeAg positive 25-year-old male patient was treated with interferon (IFN)-alpha (thrice a week 10 MU) and lamivudine (100 mg/daily) combination for one year.
  • At the end of this treatment although HBV-DNA was under the detectable limit and ALT levels returned to normal, anti-HBe antibodies did not develop.
  • During the course of lamivudin treatment on the third year virus was found to be resistant to lamivudin [FLM+YMDD+YIDD+YVDD (Inno-LiPA HBV DR, Innogenetics Ghent, Belgium)] and adefovir was added to the lamivudin therapy.
  • At the end of eight months of combination therapy, ALT levels did not return to normal and HBV-DNA was still in detectable levels.
  • On the 11th month resistance to adefovir was analysed and rtA181T mutation was found by DNA sequence analysis (Big Dye Terminator Cycle Sequencing kit, Applied Biosystems, USA).
  • Since there had been no response to adefovir from the initiation of the therapy, primary adefovir resistance was suspected.
  • Primary adefovir resistance was confirmed by the detection of the same mutation in pre-adefovir treatment serum sample of the patient.
  • Lamivudin was re-added to the therapy, however, HBV-DNA still remained positive on the third month of this combination therapy.
  • The patient got out of routine follow-up after this period.
  • [MeSH-major] Adenine / analogs & derivatives. Antiviral Agents / therapeutic use. Hepatitis B virus / drug effects. Hepatitis B, Chronic / drug therapy. Organophosphonates / therapeutic use
  • [MeSH-minor] Adult. Alanine Transaminase / blood. DNA, Viral / analysis. Drug Resistance, Viral / genetics. Drug Therapy, Combination. Humans. Interferon-alpha / therapeutic use. Lamivudine / pharmacology. Lamivudine / therapeutic use. Male

  • Genetic Alliance. consumer health - Hepatitis.
  • Hazardous Substances Data Bank. Adefovir .
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682718.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; 0 / Interferon-alpha; 0 / Organophosphonates; 2T8Q726O95 / Lamivudine; 6GQP90I798 / adefovir; EC 2.6.1.2 / Alanine Transaminase; JAC85A2161 / Adenine
  •  go-up   go-down


76. Landry M, Nagy F: [GABA(B) receptors and sensitization to pain]. J Soc Biol; 2009;203(1):87-97
Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] 14-3-3 Proteins / physiology. Allosteric Regulation. Animals. Baclofen / pharmacology. Baclofen / therapeutic use. Calcium Channels / physiology. Calcium-Binding Proteins / physiology. Chronic Disease. Dimerization. Extracellular Matrix Proteins / physiology. GABA-B Receptor Agonists. Glutamic Acid / physiology. Humans. Mice. Mice, Knockout. Nerve Tissue Proteins / physiology. Nociceptors / drug effects. Nociceptors / physiology. Posterior Horn Cells / physiology. Presynaptic Terminals / drug effects. Presynaptic Terminals / physiology. Rats. gamma-Aminobutyric Acid / physiology

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358814.001).
  • [ISSN] 1295-0661
  • [Journal-full-title] Journal de la Société de biologie
  • [ISO-abbreviation] J. Soc. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Calcium Channels; 0 / Calcium-Binding Proteins; 0 / Extracellular Matrix Proteins; 0 / GABA-B Receptor Agonists; 0 / Nerve Tissue Proteins; 0 / Receptors, GABA-B; 0 / fibulin 2; 3KX376GY7L / Glutamic Acid; 56-12-2 / gamma-Aminobutyric Acid; H789N3FKE8 / Baclofen
  • [Number-of-references] 70
  •  go-up   go-down


77. Bruder E, Meier-Ruge WA: [Intestinal neuronal dysplasia type B: how do we understand it today?]. Pathologe; 2007 Mar;28(2):137-42
Genetic Alliance. consumer health - Neuronal interstitial dysplasia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intestinal neuronal dysplasia type B: how do we understand it today?].
  • [Transliterated title] Intestinale neuronale Dysplasie Typ B: Wie verstehen wir sie heute?
  • Intestinal neuronal dysplasia type B (IND B) is currently considered to be a subtle malformation of the submucosal plexus, leading to an increased proportion of over-sized ganglia and potentially accompanied by a mild, chronic gastrointestinal motility disturbance.
  • The diagnosis of IND B is morphologically based and involves the demonstration of an increased proportion of giant ganglia in the submucous plexus related to the patient's age.
  • Morphological features of IND B may occur as an isolated finding or may be observed proximal to an aganglionic segment.
  • Future research on the basis of standardized diagnostic conditions is expected to result in a better understanding of this disease, and to reveal the cause of aberrant ganglion development.
  • [MeSH-minor] Constipation / pathology. Constipation / physiopathology. Enteric Nervous System / pathology. Ganglia / pathology. Hirschsprung Disease / pathology. Hirschsprung Disease / physiopathology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Verh Dtsch Ges Pathol. 1971;55:506-10 [4130757.001]
  • [Cites] Gut. 2001 May;48(5):671-5 [11302967.001]
  • [Cites] Z Kinderchir. 1983 Oct;38(5):305-11 [6649903.001]
  • [Cites] Eur J Pediatr Surg. 2004 Dec;14(6):384-91 [15630639.001]
  • [Cites] Pathol Res Pract. 1997;193(7):465-9 [9342751.001]
  • [Cites] Virchows Arch. 2004 Mar;444(3):239-46 [14749927.001]
  • [Cites] Pediatr Dev Pathol. 2006 Nov-Dec;9(6):444-52 [17163795.001]
  • [Cites] J Pediatr Surg. 2004 Jun;39(6):927-30 [15185227.001]
  • [Cites] Nat Genet. 2002 May;31(1):89-93 [11953745.001]
  • [Cites] Pediatr Surg Int. 2000;16(1-2):53-5 [10663836.001]
  • [Cites] Dig Dis Sci. 2002 May;47(5):1049-64 [12018900.001]
  • [Cites] Gut. 1999 Jun;44(6):853-61 [10323889.001]
  • [Cites] Eur J Pediatr Surg. 1994 Oct;4(5):267-73 [7857882.001]
  • [Cites] Int J Mol Med. 2002 Jul;10(1):101-6 [12060859.001]
  • [Cites] J Med Genet. 2000 Jul;37(7):E9 [10882761.001]
  • [Cites] J Clin Invest. 1997 Aug 15;100(4):795-801 [9259577.001]
  • [Cites] Eur J Pediatr Surg. 1994 Oct;4(5):287-92 [7857885.001]
  • [Cites] Prog Pediatr Surg. 1989;24:186-92 [2513603.001]
  • [Cites] Eur J Pediatr Surg. 2000 Feb;10(1):17-22 [10770242.001]
  • [Cites] Pediatr Surg Int. 2003 Dec;19(11):715-20 [14689210.001]
  • [Cites] Nat Med. 1997 Jun;3(6):646-50 [9176491.001]
  • [Cites] Eur J Pediatr Surg. 1994 Oct;4(5):279-86 [7857884.001]
  • [Cites] Eur J Pediatr Surg. 1994 Oct;4(5):293-7 [7857886.001]
  • [Cites] J Pediatr Surg. 2001 Aug;36(8):1293-6 [11479879.001]
  • [Cites] J Pediatr Surg. 2001 May;36(5):777-9 [11329588.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 May;3(5):423-31 [15880310.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1428-40 [14598259.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1339-42 [12468955.001]
  • [Cites] Pathobiology. 2005;72(1-2):1-102 [15902901.001]
  • [Cites] Virchows Arch. 1995;426(6):549-56 [7655734.001]
  • (PMID = 17279410.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


78. Martius P, Tech S, Stachs O, Guthoff RF: [Transpalpebral measurement of axial eye length. Use of contact B-scan sonography]. Ophthalmologe; 2010 Aug;107(8):733-9
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Axial Length, Eye / diagnostic imaging. Exophthalmos / diagnosis. Eyelids / diagnostic imaging. Microphthalmos / diagnosis. Orbit / diagnostic imaging. Ultrasonography / instrumentation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmologe. 2003 Jul;100(7):507-17 [12920550.001]
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • (PMID = 20376463.001).
  • [ISSN] 1433-0423
  • [Journal-full-title] Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
  • [ISO-abbreviation] Ophthalmologe
  • [Language] ger
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


79. Juszczyk J, Boroń-Kaczmarska A, Cianciara J, Flisiak R, Gładysz A, Halota W, Kryczka W, Malkowski P, Pawlowska M, Simon K, Polish Hepatitis B Virus Expert Group: [Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations]. Pol Merkur Lekarski; 2010 Aug;29(170):103-6
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Antiviral treatment of chronic B hepatitis; 2010 - therapeutic recommendations].
  • [Transliterated title] Leczenie przeciwwirusowe przewlekłego zapalenia watroby typu B--zalecenia terapeutyczne 2010.
  • The drugs currently approved for treatment of HBV infections are: interferon alpha2a and alpha2b, pegylated interferon (PeglFN-al-pha2a) natural interferons and nucleos(t)ide analogues (NA): adefovir, entecavir, lamivudine, telbivudine (currently not available in Poland) and tenofovir.
  • The following questions are described: the primary goal of antiviral treatment, criteria in therapeutic decision-making (including extrahepatic manifestations, compensated and decompensated cirrhosis of the liver), treatment failure (including: drug resistance), management of patients with HBV-positive markers, in whom chemotherapy or other immunosuppressive therapy is planned.
  • In treatment-naive patients with chronic hepatitis B the first line therapy should be PeglFN-alpha2a monotherapy, and the first-line should be entecavir or tenofovir (highest potential for HBV replication suppression and high genetic barrier to resistance).
  • In drug resistance the patient should be switched to another, preferably high-potency NA (entecavir or tenofovir) or start PeglFN-alpha2a therapy.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis B, Chronic / drug therapy. Practice Guidelines as Topic
  • [MeSH-minor] Adenine / analogs & derivatives. Adenine / therapeutic use. Drug Administration Schedule. Drug Resistance, Viral. Guanine / analogs & derivatives. Guanine / therapeutic use. Humans. Interferon-alpha. Liver / pathology. Organophosphonates / therapeutic use. Polyethylene Glycols. Recombinant Proteins. Tenofovir. Treatment Failure. Viral Load

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842822.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 0 / Organophosphonates; 0 / Recombinant Proteins; 0 / peginterferon alfa-2a; 30IQX730WE / Polyethylene Glycols; 5968Y6H45M / entecavir; 5Z93L87A1R / Guanine; 76543-88-9 / interferon alfa-2a; 99YXE507IL / Tenofovir; JAC85A2161 / Adenine
  •  go-up   go-down


80. Kuziemski A, Narolska-Wierczewska E, Borowiecki M, Kowalewski T, Wojdowski W: [Hepatitis B virus infections in 2002-2004 in Kujawsko-Pomorskie voivodeship]. Przegl Epidemiol; 2005;59(4):815-21
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to review epidemiological status of HBV infections in our province by using new clinical findings.
  • Diagnosis of the acute, chronic or carrier infection were agreed on the basis of interview and presented clinical, biochemical and immunoserological exponents.
  • 152 cases of acute hepatitis B were reported in analysed period.
  • The registered morbidity of acute hepatitis B was 58% lower during 3 years.
  • CONCLUSIONS: The incidence of acute hepatitis B in 2002-2004 demonstrated a strong tendency for decrease, especially among children under 9.
  • Statistical data did not differentiate new cases of hepatitis B for acute and chronic which resulted in incorrect outcomes.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Carrier State / epidemiology. Child. Child, Preschool. Hepatitis B Surface Antigens / blood. Hepatitis B Vaccines / therapeutic use. Humans. Incidence. Infant. Mass Screening. Middle Aged. Needs Assessment. Poland / epidemiology. Population Surveillance. Prevalence. Primary Prevention / methods. Rural Population / statistics & numerical data. Urban Population / statistics & numerical data

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16729422.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B Vaccines
  •  go-up   go-down


81. Menge T, Büdingen HC, Dalakas MC, Kieseier BC, Hartung HP: [Targeting B cells in multiple sclerosis. Current concepts and strategies]. Nervenarzt; 2009 Feb;80(2):190-8
MedlinePlus Health Information. consumer health - Multiple Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] B-Zell-gerichtete Multiple-Sklerose-Therapie. Aktueller Stand.
  • Multiple sclerosis (MS) is a chronic inflammatory demyelinating autoimmune disease of the CNS and a leading cause of lasting neurological disability in younger adults.
  • The results are very promising, meeting not only the primary endpoint of reduction of the surrogate MRI marker of contrast-enhancing lesions but also showing a reduction in clinical relapse rate of patients treated with rituximab.
  • This review discusses the role of autoreactive B cells in the context of MS, analyzes the B-cell-depleting treatment studies reported, and provides information on planned and future B-cell-directed therapeutic strategies in MS.

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 2001 Nov;124(Pt 11):2169-76 [11673319.001]
  • [Cites] Clin Immunol. 2008 Jun;127(3):280-5 [18337174.001]
  • [Cites] Annu Rev Med. 2008;59:237-50 [18186705.001]
  • [Cites] Int MS J. 2006 Nov;13(3):84-90 [17101076.001]
  • [Cites] Immunol Rev. 2005 Apr;204:43-54 [15790349.001]
  • [Cites] Trends Immunol. 2005 May;26(5):254-9 [15866238.001]
  • [Cites] J Clin Invest. 1998 Sep 1;102(5):1045-50 [9727074.001]
  • [Cites] Springer Semin Immunopathol. 2006 Dec;28(4):351-64 [17091246.001]
  • [Cites] Nat Immunol. 2004 Sep;5(9):943-52 [15300245.001]
  • [Cites] Ann Neurol. 2000 Jun;47(6):707-17 [10852536.001]
  • [Cites] J Neuroimmunol. 2001 Jan 1;112(1-2):1-14 [11108928.001]
  • [Cites] Nat Rev Immunol. 2006 Mar;6(3):205-17 [16498451.001]
  • [Cites] Arch Neurol. 2005 Oct;62(10):1620-3 [16216948.001]
  • [Cites] J Immunol. 1999 Nov 1;163(9):5133-44 [10528220.001]
  • [Cites] Ann Neurol. 2006 Jun;59(6):880-92 [16718690.001]
  • [Cites] J Neuroimmunol. 2004 Mar;148(1-2):11-23 [14975582.001]
  • [Cites] Blood. 1994 Jan 15;83(2):435-45 [7506951.001]
  • [Cites] J Autoimmun. 2007 Dec;29(4):287-94 [17826952.001]
  • [Cites] Pharmacol Ther. 2006 Oct;112(1):57-70 [16644016.001]
  • [Cites] Science. 1979 Mar 16;203(4385):1123-5 [424741.001]
  • [Cites] Eur J Immunol. 1999 Nov;29(11):3432-9 [10556797.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jul;5(7):564-76 [16816838.001]
  • [Cites] Nat Rev Immunol. 2001 Nov;1(2):147-53 [11905822.001]
  • [Cites] Nat Clin Pract Neurol. 2006 Apr;2(4):201-11 [16932551.001]
  • [Cites] Curr Dir Autoimmun. 2005;8:25-54 [15564716.001]
  • [Cites] J Immunol. 2007 May 15;178(10 ):6092-9 [17475834.001]
  • [Cites] FDA Consum. 2007 Mar-Apr;41(2):3 [17582852.001]
  • [Cites] J Exp Med. 1984 Oct 1;160(4):1102-13 [6207262.001]
  • [Cites] Nat Rev Drug Discov. 2006 Mar;5(3):235-46 [16474316.001]
  • [Cites] Eur J Immunol. 2008 Jul;38(7):2014-23 [18521957.001]
  • [Cites] Nervenarzt. 2007 Aug;78(8):883-911 [17551708.001]
  • [Cites] Immunity. 2007 Feb;26(2):205-13 [17306569.001]
  • [Cites] N Engl J Med. 2008 Feb 14;358(7):676-88 [18272891.001]
  • [Cites] Nat Med. 1999 Feb;5(2):170-5 [9930864.001]
  • [Cites] J Neuroimmunol. 2006 Nov;180(1-2):63-70 [16904756.001]
  • [Cites] J Autoimmun. 2007 Dec;29(4):246-9 [17888625.001]
  • [Cites] Neurology. 2005 Apr 12;64(7):1270-2 [15824362.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1486-8 [11830505.001]
  • [Cites] Ann Neurol. 2008 Mar;63(3):395-400 [18383069.001]
  • [Cites] Ann Neurol. 2000 Jun;47(6):694-706 [10852535.001]
  • [Cites] PLoS One. 2008 Jul 02;3(7):e2559 [18596942.001]
  • [Cites] Brain. 2006 Aug;129(Pt 8):1953-71 [16632554.001]
  • [Cites] J Autoimmun. 2007 Dec;29(4):219-28 [17888628.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2793-806 [16947627.001]
  • [Cites] Drugs. 2008;68(17):2445-68 [19016573.001]
  • [Cites] Nat Rev Immunol. 2003 Aug;3(8):642-55 [12974479.001]
  • [Cites] Curr Opin Rheumatol. 2008 May;20(3):263-8 [18388516.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1975-8 [16705086.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1581-7 [12874252.001]
  • [Cites] Brain. 2006 Jan;129(Pt 1):200-11 [16280350.001]
  • [Cites] Arch Neurol. 2005 Feb;62(2):258-64 [15710854.001]
  • [Cites] Lancet Neurol. 2007 Sep;6(9):805-15 [17706564.001]
  • [Cites] Drugs. 1999 Jul;58(1):79-88; discussion 89-90 [10439931.001]
  • [Cites] Science. 2003 Sep 5;301(5638):1374-7 [12920303.001]
  • [Cites] Rheumatology (Oxford). 2008 Feb;47(2):224-5 [18045807.001]
  • [Cites] Neurology. 2007 Aug 14;69(7):704-6 [17698796.001]
  • [Cites] Ann Neurol. 1999 Aug;46(2):144-60 [10443879.001]
  • [Cites] J Exp Med. 2005 Jan 17;201(2):195-200 [15642740.001]
  • [Cites] Brain. 2005 Jul;128(Pt 7):1667-76 [15800022.001]
  • [Cites] J Exp Med. 1947 Jan 1;85(1):117-30 [19871595.001]
  • [Cites] Mult Scler. 1998 Jun;4(3):111-7 [9762657.001]
  • [Cites] Brain. 2007 Apr;130(Pt 4):1089-104 [17438020.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 27;101(30):11064-9 [15263096.001]
  • [Cites] Lancet. 2005 Aug 13-19;366(9485):579-82 [16099294.001]
  • [Cites] Curr Opin Neurol. 2008 Apr;21 Suppl 1:S19-25 [18388796.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Feb;65(2):124-41 [16462204.001]
  • [Cites] N Engl J Med. 2007 Aug 30;357(9):851-62 [17660530.001]
  • [Cites] Annu Rev Immunol. 2005;23:683-747 [15771584.001]
  • [Cites] Nat Clin Pract Neurol. 2005 Nov;1(1):34-44 [16932490.001]
  • [Cites] Nat Immunol. 2002 Oct;3(10):944-50 [12244307.001]
  • [Cites] N Engl J Med. 2000 Sep 28;343(13):938-52 [11006371.001]
  • [Cites] Trends Neurosci. 2000 Jul;23(7):317-27 [10856942.001]
  • [Cites] Arthritis Rheum. 2003 Nov;48(11):3253-65 [14613291.001]
  • [Cites] Ann Neurol. 2007 Apr;61(4):288-99 [17444504.001]
  • [Cites] J Exp Med. 2005 Mar 7;201(5):703-11 [15738055.001]
  • [Cites] Immunity. 2001 Aug;15(2):289-302 [11520463.001]
  • [Cites] Ann Neurol. 1998 Feb;43(2):236-43 [9485065.001]
  • (PMID = 19189075.001).
  • [ISSN] 1433-0407
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20
  • [Number-of-references] 77
  •  go-up   go-down


82. Camara B, Faye PM, Diouf S, Gueye-Diagne NR, Diagne I, Cissé MF, Ba M, Sow HD, Kuakuvi N: [Pédiatric haemophilus influenzae b meningitis in Dakar]. Med Mal Infect; 2007 Nov;37(11):753-7
MedlinePlus Health Information. consumer health - Haemophilus Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinical evolution is marked by death (17.8%) and recovery with psychological, sensory, and motor sequels (19.9%).

  • Genetic Alliance. consumer health - Haemophilus Influenzae.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629648.001).
  • [ISSN] 0399-077X
  • [Journal-full-title] Médecine et maladies infectieuses
  • [ISO-abbreviation] Med Mal Infect
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


83. Mylonas I, Gutsche S, Anton G, Jeschke U, Weissenbacher ER, Friese K: [Parvovirus B 19 infection during pregnancy]. Z Geburtshilfe Neonatol; 2007 Apr;211(2):60-8
MedlinePlus Health Information. consumer health - Infections and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meanwhile, parvovirus B 19 infections can be associated with a wide spectrum of hematological and non-hematological complications (e.g. liver failure, hepatitis, aplastic crises primarily in association with chronic hemolytic anaemias, chronic arthritis, arthralgia/arthritis, transient/persistent anaemias, vasculitis, glomerulonephritis).
  • Investigation for the development and clinical testing of an efficient vaccine against parvovirus B 19 is currently in progress.
  • [MeSH-major] Erythema Infectiosum / diagnosis. Parvoviridae Infections / diagnosis. Parvovirus B19, Human / pathogenicity. Pregnancy Complications, Infectious / diagnosis

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Fifth Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17486526.001).
  • [ISSN] 0948-2393
  • [Journal-full-title] Zeitschrift für Geburtshilfe und Neonatologie
  • [ISO-abbreviation] Z Geburtshilfe Neonatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 109
  •  go-up   go-down


84. Cicenas S, Zaliene A, Atkocius V: [Treatment outcome of locally advanced stage IIIA/B lung cancer]. Medicina (Kaunas); 2009;45(6):452-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine survival of patients with stage IIIA/B non-small cell lung cancer considering disease stage and treatment methods.
  • MATERIAL AND METHODS: A total of 304 patients with non-small cell lung cancer were treated at the Department of Thoracic Surgery and Oncology, Institute of Oncology, Vilnius University, in 2000-2004.
  • According to morphology, there were 219 (72%) patients with squamous cell lung cancer, 80 (26.3%) with adenocarcinoma, and 5 (1.7%) patients with large cell carcinoma.
  • CONCLUSIONS: Disease stage had an influence on the survival of patients with non-small cell lung cancer: patients with stage IIIA (T3N0-1M0) cancer without metastases to mediastinal lymph nodes (N factor) survived longer than patients with stage IIIB (T4N1-2M0) cancer, where not only N factor had an impact but T factor as well.
  • Better treatment outcomes, i.e. longer survival, can be achieved when a combination of three treatment types - surgery, chemotherapy, and radiation therapy - is applied to patients with stage IIIA or IIIB non-small cell lung cancer.
  • The patients with stage IIIA disease who received surgery and radiation therapy (total dose, >40 Gy), and combinations of surgery, chemotherapy, and radiation therapy and second-line chemotherapy showed a significantly longer survival than those who received surgery alone.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Antineoplastic Agents / therapeutic use. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / pathology. Combined Modality Therapy. Female. Humans. Kaplan-Meier Estimate. Lung / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Palliative Care. Radiotherapy Dosage. Thoracotomy. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605965.001).
  • [ISSN] 1648-9144
  • [Journal-full-title] Medicina (Kaunas, Lithuania)
  • [ISO-abbreviation] Medicina (Kaunas)
  • [Language] lit
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Lithuania
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


85. Klitfod L, Baekgaard N, Just S, Skøtt P, Jensen LP: [Modern treatment of type B dissections]. Ugeskr Laeger; 2008 Sep 8;170(37):2858-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modern treatment of type B dissections].
  • [Transliterated title] Moderne behandling af type B-aortadissektion.
  • Rapid classification is essential in the management of aortic dissections, as Type A dissections require surgery, while the optimal treatment of Type B dissections is controversial.
  • Medical treatment with antihypertensive medication and analgesics has so far been the main treatment of uncomplicated Type B dissections, while surgery has been reserved for complications and persistent pain in spite of medical treatment.
  • [MeSH-minor] Antihypertensive Agents / therapeutic use. Chest Pain / diagnosis. Diagnosis, Differential. Early Diagnosis. Follow-Up Studies. Humans. Prognosis. Stents. Survival Rate. Treatment Outcome. Vascular Surgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18796278.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antihypertensive Agents
  • [Number-of-references] 36
  •  go-up   go-down


86. Jacquot S, Boyer O: [Heterogeneity and function of human B lymphocytes]. Med Sci (Paris); 2006 Dec;22(12):1075-80
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Besides their main function of providing antibodies protecting against pathogens, they also exert some regulatory functions, in particular for secondary lymphoid tissue differentiation.
  • Naïve IgMlow IgDhigh CD27- B cells can participate in T-cell dependent immune responses leading to germinal center formation in follicles of secondary lymphoid organs.
  • Interactions with follicular helper T cells, a recently identified CD185+ T cell population providing help to follicular B cell, involve costimulatory molecules including CD40, CD27, CD278 and SAP-recruiting receptors.
  • B cell interaction with follicular helper T cells represents a critical step controlling the generation of plama cells that ultimately produce high affinity, somatically mutated, class-switched antibodies or of their memory B cell counterpart (identified as CD27+ Ig switched or IgMonly B cells).
  • All together, deciphering human B cell heterogeneity provides tools for investigations of humoral immunodeficiencies and auto-immune diseases, that will in return shed more light on B cell biology.
  • [MeSH-minor] Antigens, CD / immunology. B-Lymphocyte Subsets / immunology. Cell Differentiation. Humans. Immunoglobulin Class Switching / immunology. Lymphocyte Activation. Models, Immunological. Phenotype

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156729.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, CD
  • [Number-of-references] 40
  •  go-up   go-down


87. Mulić R, Uglesić L, Klismanić Z, Ropac D, Smoljanović M, Mratinović-Mikulandra J, Aleraj B, Lucev O: [Epidemiologic characteristic of hepatitis B in the Splitsko-Dalmatinska County]. Lijec Vjesn; 2006 Mar-Apr;128(3-4):65-71
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiologic characteristics of hepatitis B virus (HBV) infection in the Split-Dalmatia County and in Croatia as a whole from January 1, 1994 till December 31, 2003 were analyzed.
  • The hepatitis B mortality rate was 0.24% (5/2079) in Croatia as a whole, whereas no case of HBV lethality was recorded in the Split-Dalmatia County.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16808093.001).
  • [ISSN] 0024-3477
  • [Journal-full-title] Lijec̆nic̆ki vjesnik
  • [ISO-abbreviation] Lijec Vjesn
  • [Language] hrv
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


88. Marín López ER, Grupo del Consenso de Hepatitis: [First National Consensus on Chronic Hepatitis B]. Rev Gastroenterol Mex; 2005 Oct-Dec;70(4):490-503
Genetic Alliance. consumer health - Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Primer Consenso Nacional de Hepatitis B Crónica.
  • With the new sensitive diagnostic methods, new antivirals capable of inhibiting viral replication, the appropriate use of passive and active immunoprophilaxis, and the better understanding of the natural history of the disease, we are finding new corners in the approach of high risk groups and management of infected patients.
  • During these rounds the need of incorporating new knowledge on Hepatitis B in our daily clinical practice was analyzed in a way to transform Hepatitis B to an understandable and easy subject.
  • [MeSH-major] Hepatitis B, Chronic / diagnosis. Hepatitis B, Chronic / drug therapy
  • [MeSH-minor] Disease Progression. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17058992.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Consensus Development Conference; English Abstract; Journal Article
  • [Publication-country] Mexico
  • [Number-of-references] 27
  •  go-up   go-down


89. Biringer K, Biskupská Bod'ová K, Hasko M, Dókus K, Danko J, Stillová L, Biringerová Z: [Streptococci group B in perinatology]. Ceska Gynekol; 2010 Oct;75(5):435-8
MedlinePlus Health Information. consumer health - Streptococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Streptococci group B in perinatology].
  • [Transliterated title] Streptokoky skupiny B v perinatológii.
  • OBJECTIVE: Assessment of screening and prophylaxis of streptococci group B (GBS).
  • DESIGN: Retrospective study.
  • SETTING: Department of Gynecology and Obstetrics, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic.
  • METHODS: Groups of patients: A-GBS negative (n=601), B-GBS positive (n=166), and C-unknown GBS status (n=238).
  • RESULTS: We assessed 1005 deliveries; antenatal screening was done in 767 patients (166 GBS positive).
  • Intrapartal antibiotic prophylaxis (IAP) was the most frequent in group B (75.3%), (A-10.0%, C-15.0%).
  • The most common antibiotics: ampicillin, and cephalosporins of the 1st and 2nd generation.
  • The interval from rupture of membranes (ROM) to the first IAP dose was significantly the shortest in group B.
  • The longest interval from ROM to delivery was in group A (490 min.).
  • CONCLUSION: This study shows the possibilities for improvement in GBS prophylaxis, in unknown GBS status, and preterm delivery, particularly.

  • MedlinePlus Health Information. consumer health - Infections and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21374920.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] SLO
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


90. Vildozola H: [Vaccination against Hepatitis B: 20 years later]. Rev Gastroenterol Peru; 2007 Jan-Mar;27(1):57-66
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • More than 20 years have elapsed since 1984, when vaccination against Hepatitis B began, first with a plasma-derived vaccine and later a recombinant DNA-derived vaccine, and during this period important changes have taken place in several aspects of this disease: the acute and chronic infection rates, the mortality of fulminant Hepatitis B in infants and the incidence of hepatocellular carcinoma have been effectively reduced by approximately 25%.
  • It has also been proposed that there is an increased risk of non-response to the Hepatitis B vaccine among elderly people.

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431429.001).
  • [ISSN] 1022-5129
  • [Journal-full-title] Revista de gastroenterología del Perú : órgano oficial de la Sociedad de Gastroenterología del Perú
  • [ISO-abbreviation] Rev Gastroenterol Peru
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Peru
  • [Chemical-registry-number] 0 / Hepatitis B Surface Antigens; 0 / Hepatitis B Vaccines
  • [Number-of-references] 97
  •  go-up   go-down


91. Couderc J: [B lymphocytes--a dogma revisited]. C R Biol; 2005 Aug;328(8):758-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Un lymphocyte B--un anticorps : le dogme ébranlé.
  • The one B cell-one antibody hypothesis proposed by M.F.
  • Burnet (1957) was recently challenged by results showing that one B cell can simultaneously express an auto-reactive BCR, and a BCR directed against non-self antigens.
  • The latter allows this auto-reactive B cell to escape negative selection.
  • [MeSH-minor] Animals. Antibody Diversity. Erythrocytes / immunology. Kinetics. Models, Immunological. Receptors, Antigen, B-Cell / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125653.001).
  • [ISSN] 1631-0691
  • [Journal-full-title] Comptes rendus biologies
  • [ISO-abbreviation] C. R. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Receptors, Antigen, B-Cell
  • [Number-of-references] 38
  •  go-up   go-down


92. Pedersen H, Engberg JH, Oturai PS: [Acute multifocal osteomyelitis caused by haemolytic group B streptococci]. Ugeskr Laeger; 2006 Feb 6;168(6):589-90
MedlinePlus Health Information. consumer health - Streptococcal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute multifocal osteomyelitis caused by haemolytic group B streptococci].
  • [MeSH-minor] Acute Disease. Aged. Female. Humans. Penicillins / administration & dosage

  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476223.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Penicillins
  •  go-up   go-down


93. Kohlhaas K, Brechmann T, Vorgerd M: [Hepatitis B associated polyarteriitis nodosa with cerebral vasculitis]. Dtsch Med Wochenschr; 2007 Aug;132(34-35):1748-52
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HISTORY AND ADMISSION FINDINGS: A 53-year-old male was admitted with an acute brainstem syndrome.
  • Because of the worsening neurological symptoms he was admitted to our neurological clinic five months after onset of the disease.
  • On admission he showed signs of a productive psychosis in addition to akinetic-rigid parkinsonism and cerebellar symptoms.
  • DIAGNOSIS, THERAPY AND COURSE: The laboratory and neuroradiological studies indicated a hepatitis B-associated polyarteriitis nodosa and cerebral vasculitis.
  • Later he was given prednisolone (60 mg daily) and lamivudine (100 mg daily) again which has so far stabilized the clinical course.
  • Depending on the course of the disease an escalating steroid pulse administration and plasmaphereses should be considered.
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Diagnosis, Differential. Hepatitis B Surface Antigens / analysis. Humans. Lamivudine / therapeutic use. Male. Middle Aged. Prednisolone / therapeutic use. Reverse Transcriptase Inhibitors / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Vasculitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • Hazardous Substances Data Bank. LAMIVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713883.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antiviral Agents; 0 / Hepatitis B Surface Antigens; 0 / Immunosuppressive Agents; 0 / Reverse Transcriptase Inhibitors; 2T8Q726O95 / Lamivudine; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


94. Göbel T, Erhardt A, Richter J, Poremba C, Häussinger D: [Chronic hepatitis B with an unexpected coinfection]. Med Klin (Munich); 2010 Nov;105(11):827-30
Genetic Alliance. consumer health - Hepatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: Patients from tropical countries suffering from chronic viral hepatitis may present with additional coinfections which can be earily overlooked in daily clinical routine.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Trop. 2000 Oct 23;77(1):9-40 [10996118.001]
  • [Cites] Gastroenterology. 2009 Dec;137(6):2002-9 [19737568.001]
  • [Cites] Hepatol Res. 2007 Dec;37(12):1002-10 [17608672.001]
  • [Cites] Ann Trop Med Parasitol. 1994 Oct;88(5):501-9 [7979640.001]
  • [Cites] J Hepatol. 2009 Feb;50(2):227-42 [19054588.001]
  • [Cites] J Med Virol. 2009 Oct;81(10):1716-20 [19697400.001]
  • [Cites] Lancet. 2006 Sep 23;368(9541):1106-18 [16997665.001]
  • [Cites] J Med Virol. 2000 Jul;61(3):362-6 [10861647.001]
  • [Cites] Hepatology. 2006 Apr;43(4):771-9 [16557547.001]
  • [Cites] Liver. 2000 Jul;20(4):281-9 [10959806.001]
  • [Cites] J Hepatol. 1997 Feb;26(2):236-43 [9059941.001]
  • [Cites] Acta Trop. 2003 May;86(2-3):161-83 [12745135.001]
  • [Cites] Parasitol Today. 1998 Oct;14(10):418-22 [17040833.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):65-73 [16391218.001]
  • [Cites] Parasite Immunol. 2006 Oct;28(10):483-96 [16965284.001]
  • [Cites] Hepatology. 1994 Jun;19(6):1513-20 [8188183.001]
  • [Cites] Ann Intern Med. 2009 Jan 20;150(2):104-10 [19124811.001]
  • [Cites] Acta Trop. 2000 Oct 23;77(1):41-51 [10996119.001]
  • [Cites] J Med Virol. 2003 Aug;70(4):529-36 [12794714.001]
  • [Cites] Liver Int. 2009 Feb;29(2):242-7 [18637064.001]
  • [Cites] J Med Virol. 1994 Feb;42(2):203-6 [8158115.001]
  • (PMID = 21136241.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Schistosomicides; 6490C9U457 / Praziquantel
  •  go-up   go-down


95. Andersen ES, Weis NM: [New treatment of chronic hepatitis B]. Ugeskr Laeger; 2008 Nov 24;170(48):3937-9
Hazardous Substances Data Bank. LAMIVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New treatment of chronic hepatitis B].
  • [Transliterated title] Ny behandling af kronisk hepatitis B.
  • Worldwide, 350 million people are infected with chronic hepatitis B.
  • Over the last few years, it has been possible to treat chronic hepatitis B.
  • Treatment very often consists of nucleos(t)ide analogs and in a few cases of pegylated alpha-interferon.
  • In 2007, a new nucleoside analog, Telbivudine, was approved to treat chronic hepatitis B.
  • In phase II and ongoing phase III studies, Telbivudine has proven more effective than the nucleoside analog, Lamivudine, which was very often used up until recently.
  • [MeSH-major] Antiviral Agents / therapeutic use. Hepatitis B, Chronic / drug therapy
  • [MeSH-minor] Humans. Lamivudine / administration & dosage. Lamivudine / adverse effects. Lamivudine / therapeutic use. Nucleosides / administration & dosage. Nucleosides / adverse effects. Nucleosides / therapeutic use. Pyrimidinones / administration & dosage. Pyrimidinones / adverse effects. Pyrimidinones / therapeutic use. Reverse Transcriptase Inhibitors / therapeutic use. Thymidine / analogs & derivatives

  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087730.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Nucleosides; 0 / Pyrimidinones; 0 / Reverse Transcriptase Inhibitors; 2OC4HKD3SF / telbivudine; 2T8Q726O95 / Lamivudine; VC2W18DGKR / Thymidine
  •  go-up   go-down


96. Arfaoui D, Fkih M, Hafsa AE, Kaabia N, Azzouz M: [Hepatitis B and pregnancy]. Tunis Med; 2010 Jun;88(6):383-9
MedlinePlus Health Information. consumer health - Infections and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Fetal Diseases / virology. Hepatitis B / transmission. Infectious Disease Transmission, Vertical. Pregnancy Complications, Infectious


97. Caner M, Arat S, Bircan R: [Development of a hepatitis B virus carrier transgenic mice model]. Mikrobiyol Bul; 2008 Jan;42(1):71-81
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Development of a hepatitis B virus carrier transgenic mice model].
  • [MeSH-major] Carrier State / immunology. Disease Models, Animal. Hepatitis B / etiology. Hepatitis B virus / genetics. Mice, Transgenic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18444564.001).
  • [ISSN] 0374-9096
  • [Journal-full-title] Mikrobiyoloji bülteni
  • [ISO-abbreviation] Mikrobiyol Bul
  • [Language] tur
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


98. Porsová-Dutoit I: [Place of inhibin B investigation in clinical andrological praxis]. Vnitr Lek; 2008 Nov;54(11):1059-62

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Place of inhibin B investigation in clinical andrological praxis].
  • Inhibin B blood level knowledge can be a useful tool in the management of difficult diagnostic problems, such as ambiguous genitalia, the distinction between cryptorchidism and anorchidism and the hypogonadotrophic hypogonadism/delayed puberty differential diagnosis.
  • Inhibin B measurements can help in gonadal dysgenesis evaluation, androgen insensitivity management and also in the diagnosis of some gonadal tumors.
  • [MeSH-major] Gonadal Disorders / diagnosis. Inhibins / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069679.001).
  • [ISSN] 0042-773X
  • [Journal-full-title] Vnitr̆ní lékar̆ství
  • [ISO-abbreviation] Vnitr Lek
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers; 0 / inhibin B; 57285-09-3 / Inhibins
  • [Number-of-references] 47
  •  go-up   go-down


99. Bacq Y: [Hepatitis B and pregnancy]. Gastroenterol Clin Biol; 2008 Jan;32(1 Pt 2):S12-9
MedlinePlus Health Information. consumer health - Infections and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Hepatitis B, Chronic / transmission. Infectious Disease Transmission, Vertical / prevention & control. Pregnancy Complications, Infectious / prevention & control

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18662605.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hepatitis B Antigens; 0 / Hepatitis B Vaccines
  • [Number-of-references] 50
  •  go-up   go-down


100. Magdzik W, Czarkowski MP: [Coverage of vaccination against hepatitis B in Poland in 2004]. Przegl Epidemiol; 2006;60(2):185-92
MedlinePlus Health Information. consumer health - Hepatitis B.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Coverage of vaccination against hepatitis B in Poland in 2004].
  • [Transliterated title] Stan zaszczepienia przeciwko wirusowemu zapaleniu watroby typu b w Polsce do końca 2004 roku.
  • Vaccinations against hepatitis B were performed according to Programme of Vaccination since 1989.
  • 31,1% of population was vaccinated at the and of 2004.
  • In voivodships vaccination was performed between 38,2% and 27,6% Children and adolescents up to 19 years old were vaccinated in 77,6% and persons older than 20 in 15,6%.
  • In the next 2-4 years all children, adolescents and young adults up to 23 should be vaccinated against hepatitis B in Poland in 95% or even more.
  • [MeSH-major] Child Welfare. Hepatitis B / epidemiology. Hepatitis B / prevention & control. Hepatitis B Vaccines / therapeutic use. Immunization Programs / organization & administration
  • [MeSH-minor] Age Distribution. Child. Humans. Incidence. Infant. Infant, Newborn. Poland / epidemiology. Retrospective Studies. Rural Population / statistics & numerical data. Urban Population / statistics & numerical data

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16964668.001).
  • [ISSN] 0033-2100
  • [Journal-full-title] Przegla̧d epidemiologiczny
  • [ISO-abbreviation] Przegl Epidemiol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down






Advertisement